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2.ABSTRACT
BIOTRANSFORMATION OF POLYMETHOXYFLAVONES
AND ITS IMPLICATION ON BIOLOGICAL ACTIVITIES
MAY 2017

MINQI WANG, B.Eng., CHINA AGRICULTURAL UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Hang Xiao

In this thesis, the tissue distribution and in vivo biotransformation of nobiletin in rodents
were demonstrated on three types of rodents, i.e.A-J female mice, CD-1 male mice and male
F344 male rats. The effects of colonic metabolites of CD-1 mice on colonic carcinogenesis and
inflammation were determined.
In order to mimic the long-term dietary consumption of PMFs from food or dietary
supplements, we applied oral administration by mixing PMFs with standard diet to rodents who
have free access to food. Moreover, nobiletin (NBT), one of the most abundant PMFs in nature,
and its major metabolties were incubated with mice liver S9 to investigate the in vitro
biotransformation in liver. The digesta (food under digestion) from small intestine of mice orally
adminsitrated with NBT were collected and incubated with microflora from of mice administrated
with base diet to investigate the effects of microbiome on biotransformation. NBT and its three
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metabolites, i.e. 3’-demethylnobiletin (N1), 4’-demethylnobiletin (N2), and 3’, 4’-didemethylnobiletin (N3) in tissues ranging from brain, kidney, liver, spleen, stomach, small
intestine, cecum, colon and blood of three different rodents were determined by HPLC.
The results showed that PMFs was extensively metabolized to N1, N2 and N3 as well as
their glucuronide/sulfate conjugates. N2 was the most abundant metabolite for all types of
rodents. In the contrast to the metabolites in small intestine, where conjugated metabolites
dominant, most metabolites colon were in free form. The microflora was proved to be able to
deconjugate the metabolites, producing free form metabolites which possess higher bioactivities
than parent compound and their conjugates counterparts.
Considering the high level of the bioactive metabolites localized in colonic mucosa, we
further investigated the anti-cancer and anti-inflammation effect of metabolites localized in colon.
The results suggested that the anti-cancer and anti-inflammation effect of orally administrated
nobiletin was induced by the colonic metabolites. These metabolites complex can induce cell
cycle arrest and apoptosis in cancer cells.
As a summary, these studies provided a thorough information of PMFs in vivo
biotransformation, the tissue distribution of biological activity related metabolites as well as the
implication of the metabolism on colorectal cancer and inflammation.
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CHAPTER 1
9.INTRODUCTION

PMFs are a group of flavonoids found exclusively in citrus fruits, especially in their
peels. Their health beneficial bioactivities have been recognized and studied within the recent
years. Accumulating evidence demonstrated the superior pharmacological properties of PMFs
such as anti-cancer, anti-inflammatory and anti-angiogenic activities.
Many pharmacological active compounds may show specific and potent healthpromoting activities when assessed by in vitro assays. However, when they are given orally with
diet or as dietary supplements, they will be subjected to extensive biotransformation mediated by
drug-metabolizing enzymes, which may produce metabolites with different bioactivities in
comparison with the parent compounds.
Therefore, it is critical to establish the detailed understanding of the biotransformation
and tissue distribution of dietary compounds in order to better understand their mechanism of
action and potential health benefits. Despite all the studies on chemopreventive properties of
PMFs, the biotransformation and tissue distribution of PMFs are still largely unknown.
Biotransformation plays principal roles in the biological activities of orally
ingested bioactive components. The metabolites generated in the body after oral ingestion may
have different bioactivities. The metabolites generated in the body after oral ingestion may have
different bioactivities. On the other hand, in certain organ or tissue, metabolites achieve higher
concentrations than their parent compound. Therefore, the metabolites, rather than the ingested
components, may exhibit dominant biological effects in that organ or tissue. Therefore, the
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molecular mechanisms that involved in the anti-carcinogenic effects of the colonic metabolites of
PMFs may be closely associated with their application.
Therefore, the main objective of the research is to elucidate the tissue distribution of
PMFs and their metabolites after long-term oral administration and predict the bioactivities of
PMFs as dietary intakes.
Our long-term goal is to elucidate the bioactivities and bioavailability of diet-based
PMFs administration. To reach that goal, the overall objective of this project is to determine the
available levels of bioactive compounds (parent compounds as well as its metabolites) of PMFs in
vivo after oral administration. Our central hypothesis is PMFs are extensively biotransformed in
vivo and their metabolites are able to exhibit anti-inflammatory and anti-cancer activities. As a
result, the dietary intake of PMFs will exhibit stronger bioactivities than applying directly to the
target tissues.
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We will test our central hypothesis and achieve our objective by utilizing the
following four specific aims:

1. Characterize the tissue distribution of polymethoxyflavones (PMFs) and their metabolites
A/J mice model will be used to investigate the tissue distribution and accumulation of
nobiletin (NBT) after long-term oral administration. The tissues including liver, spleen, brain,
stomach, small intestine, colon and serum will be collected after 14 weeks of oral administration.
The levels of NBT, as well as its three identified metabolites in the tissues will be determined by
using HPLC-ECD and HPLC-MS methods. The quantification of conjugated metabolites will be
performed by utilizing enzymatic hydrolysis method.
2. Characterize the in vitro and in vivo biotransformation of PMFs in GI tract
The levels of NBT in A/J mice small intestine, cecum and colon will be determined by HPLC
to eliminate the interference of digesta/feces in stomach, small intestine, cecum and colon.
Immediately after the removal of stomach, small intestine, cecum and colon, half of the samples
were cut open and digesta were washed off with PBS. Small intestine will be cut tetra section. All
tissues will be analyzed using enzyme hydrolysis method followed by HPLC characterization.
The levels of parent compound and metabolites will be determined to elucidate the distribution in
GIT, in order to analyze the biotransformation pathways. Further, NBT, N1, N2 and N3 will be
incubated with mice liver S9 phase in vitro to demonstrate the role of liver play in the
biotransformation. Last but not the least, SI digesta will be collected to incubate with colonic
microflora to elucidate the biotransformation affected by microbiome.
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3. Characterize the different biotransformation pattern of PMFs across rodent types
Three rodent types, i.e. A/J female mice, CD-1 male mice and F344 male rats will be
used to compare the accumulation and biotransformation of nobiletin (NBT) after long-term
oral administration across the rodent types. GIT tissues and digesta including stomach, small
intestine and colon as well as featured peripheral tissues and serum will be collected after 14
weeks of oral administration at the same dosage (500ppm). The similarities and differences
will provide valuable guidelines on the translation of the conclusion from studies on one
species to another.
4. Determine the biological activities of NBT and its colonic metabolites on colorectal cancer
and inflammation
CD-1 male mice will be maintained on nobiletin enriched diet for 9 weeks and the feces
will be collected during the oral administration. NBT metabolites from feces will be collected
as treatments for cell culture studies. These metabolites will include identified metabolites,
i.e. N1, N2 and N3 as well as many unknown metabolites. The molecular pathways of the
biological activities will also be investigated by flow cytometry and immunoblotting. The
results will be compared with NBT treated at the same concentration to elucidate the NBT
oral efficacy on colonic diseases due to in vivo biotransformation.
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CHAPTER 2
10.LITERATURE REVIEW

2.1 Dietary bioactive compounds

While food is generally considered as the nutrients for nourishment, some components in
food are not essential in the sustenance of life. However, these non-essential agents may have
health promotion, disease prevention and performance improving effects that contribute to the
well-being [1]. As suggested by thousands of studies, these well-being promoting agents are
mainly derived from fruits and vegetables. The 2010 Dietary Guidelines for Americans
recommend nine servings of fruits and vegetables based on 2000 kcal diet [2]. However, these
protective effects are due not only to fiber, vitamins and minerals, but also to various
phytochemicals in plants. More than 5000 phytochemicals have been identified and isolated from
fruits and vegetables so far. These compounds can be classified into a few categories according to
their structures: phenolic, alkaloids, nitrogen-containing compounds, organosulfur compounds,
fatty acids phytosterols and carotenoids [3].

2.1.1 Flavonoids

Flavonoids are a group of polyphenolic phytochemicals found in almost all types of
plants. Epidemiological studies have shown that high consumption of flavonoids is associated
with low risk of chronic diseases. Flavonoids are the products of secondary metabolism in all
plants and are extensively found in cereals, legumes, nuts, olive oil, vegetables, fruits, tea, and red
wine [4]. Evidences support that flavonoids can prevent the initiation and the development of
cardiovascular disease (CVD), cancer and other health benefits. Most of the studies to date are
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concentrated on the in vitro effects of flavonoid aglycones. It has also been reported that there are
structure/activity relationships suggesting the activities of flavonoids are dependent on the
number and position of the hydroxyl substituents on the aglycone backbone [5].

2.1.2 Polymethoxyflavones

Polymethoxyflavones are a group of flavonoids that contain multiple methoxy groups.
Nobiletin can efficiently inhibit the development of cancer through many mechanisms [6],
includes assisting other anti-cancer agents, sensitizing the cell, as well as combination therapy
of nobiletin with other chemotherapeutic drugs [7].
In addition, nobiletin also possesses neuroprotective effect. Nobiletin can protect against the
oxidative stress-induced cell damage which is essential in the development of Alzheimer's disease
and Parkinson's disease[8].
Moreover, nobiletin can also alleviate scratching behavior [9], presumably by
suppressing activation of phosphoinositide 3-kinase and release the allergic effect.
Furthermore, nobiletin can assist lipid metabolism [10], protect against obesity and
insulin resistance.
Last but not least, nobiletin can also prevent cardiac hypertrophy, and
hypercholesterolemia [11].
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2.2 Introduction to biotransformation

Since the health promoting agents in food are subjected to digestion, understanding of the
digestive fate of bioactive food components is crucial in the elucidation and prediction of the
efficacy of these compounds. To fully understand the disposition and biotransformation of dietary
bioactive components after oral consumption, the bioavailability, liberation from a food matrix,
absorption, distribution, metabolism and elimination phases (LADME) should be investigated.

2.2.1 Oral bioavailability

Theoretically, the bioavailability of an administered substance is that fraction of the dose
that reaches the general circulation unchanged. Dietary bioactive compounds are regarded as
xenobiotics by human body. As a self-defense mechanism, our body will take actions to eliminate
them as much as possible. It may be considered redundant to study the health effects of dietary
bioactive compounds if their bioavailability is not understood [12] . The efficacies of compounds
are closely associated with the bioavailability since the compounds need to be bioavailable in
order to exert any health beneficial effects. The bioavailability is determined by their ability to
enter the target cells. There are several factors that affect the bioavailability, such as the ability to
withstand food processing, penetrate the gut wall, bioaccessibility, the ability of constituents to be
released from food matrix, transporters, molecular structures as well as metabolizing enzymes.

Bioaccessibility is the amount of compounds released from the food matrix in the
gastrointestinal lumen and thereby made available for intestinal absorption. It is influenced by the
composition of food matrix, physicochemical properties with the aids of bile, pancreatic and
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enzymes from intestinal mucosa. These digestive secretes are particularly crucial for the
emulsification and absorption of lipid soluble compounds.
The typical journey of a dietary bioactive compound after oral consumption is as follows:
As shown in figure 2.1, when compound reaches the GI tract, only part of them can be
absorbed due to the degradation in internal environment, physical inactivation through binding,
metabolism in transit through the gut wall, microbial biotransformation, etc. The unchanged
compound will be delivered to liver through the hepatic portal vein and are subjected to the firstpass effect. In liver, the unchanged compounds will further be metabolized, and part of the
compounds will be transported back to intestinal lumen by biliary excretion. Finally, the survived
unchanged compounds will further elimination may occur between the hepatic vein and
peripheral vein/artery.
Diet, genetic background, gut microbiota composition are three major factors that may
affect bioavailability among different individuals [13].
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Figure 2.1 Schematic representation of drug movement in the body[14].

2.2.2 Tissue Distribution

To produce health beneficial responses, bioactive compounds have to combine with
action sites, thereby cause biochemical or physicochemical alterations. The effect the compound
produce is dependent on the concentration of the unbound compound surrounding the action site
(or biophase). Yet, this concentration is seldom known. To estimate the effects of a compound,
researchers usually use the blood level (bioavailability) as a reference and assume that the tissue
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levels are the same. This assumption is based on the fact that blood is the physiological medium
of exchange between all tissues.
However, there are several factors that may cause the difference between the blood level
and tissue level of a compound, making the assumption invalid. For instance, polar compounds
cannot penetrate the membrane effectively such as the blood-brain barrier. Therefore, their level
in brain is much lower than that in blood. In addition, transport system can help the transverse of
certain compounds, making them concentrated in certain sites. Moreover, some compounds can
be rapidly metabolized in metabolic organs and be hardly found in plasma. Last but not the least,
the changing of the pH of cells and plasma may also cause the difference of levels in tissues and
blood stream.
Binding of the active compounds with components in blood and tissues may also result in the
decrease of the concentration of the unbound compound. Overall, the binding of bioactive
compounds is determined by the combination with proteins and other constituents in blood and
tissues. In blood stream, compounds can bind to proteins (mainly serum albumin) with different
affinities. In tissues, the situation is more complicated. Other than protein, certain compounds can
specifically combine with DNA, melanin, phospholipids and adipose tissue[15].

2.2.3 Metabolism

Most of flavonoids naturally occurred as glycosides in plants, which means glycoside
moieties are attached to the flavonoids backbone [5], e.g. quercetin. For the glycosides,
hydrolysis is the first step of the metabolism, resulting in the release of the aglycone, which is the
deglycosided counterpart of glycosylated flavonoids. This step is completed mainly by the action
of lactase phloridzin hydrolase (LPH) in the brush-border of the small intestine epithelial cells
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[16]. Another way of hydrolysis occurs inside of epithelial cells. Therefore, it requires the assist
of active sodium-dependent glucose transporter SGLT1 to transport the compound into the cells,
then the hydrolysis is mediated by a cytosolic β-glucosidase (CBG) [17].
On the other hand, aglycone may enter epithelial cells by passive diffusion [17]. Then
with the action of sulfotransferases (SULT), uridine-5-diphosphate glucuronosyltransferases
(UGTs) and catechol-o-methyltransferases (COMT), aglycones are metabolized into sulfate,
glucuronide and/or methylated metabolites. Some of the metabolites may be transported back to
the lumen by efflux which involves the action of the adenosine triphosphate (ATP)-binding
cassette (ABC) family of transporters, including multidrug resistance protein (MRP) and Pglycoprotein (P-gp).
Next, compounds and metabolites are transported to liver through hepatic circulation.
Once reaches liver where many phase I and phase II metabolism enzymes are located, parent
compounds and metabolites can be further converted. Through enterohepatic recirculation, part of
the resultant compounds can be recycled back to the small intestine through bile excretion [18].
The rest of compounds will pass from the small intestine to the large intestine [19] where the
colonic microbiome will further biotransform the conjugated metabolites back to aglycone by
cleaving conjugating moieties. Subsequently, the resultant compounds will undergo ring fission
leading to the production of smaller molecules.
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Figure 2.2 Intestinal metabolites systems: the cytochrome P450 (CYP) system, the UDPglucuronosyltransferases (UGTs) and sulfotransferases (SULTs) (Adopted from Li Zhang, et al.
Intestinal and Hepatic Glucuronidation of Flavonoids)

2.2.4 Microbial biotransformation

Gut microbiome (microbial genetic repertoire) consists of a large density of microbes
which can exist synergy within the human host. An estimate of 1000 distinct bacterial species 1 ×
1014 microorganisms can be found in the large intestine of human body [20]. Gut microbiome is
crucial in the biotransformation of flavonoids. When bioactive compounds and their metabolites
pass down from small intestine lumen to the large intestine, they will be exposed to the gut
microbiome. The gut microbiome is involved in the reduction and deconjugation generating nonpolar low molecular weight metabolites and byproducts such as CO2 [21]. These metabolites are
often better absorbed than their parent compounds [22].
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Gut microbiome produce different types of enzymes that assist the biotransformation of
flavonoids. First of all, O- and C-deglycosidases and hydrolases are the enzymes that involve in
the cleavage of the glycosides of flavonoids that was not metabolized in small intestine.
Secondly, glucuronidase and sulphatase can also be produced by gut microbiome which will
deconjugate the phase II metabolites. The resultant metabolites can be further degraded by gut
microbiome to smaller molecules by backbone rupture [23]. Some other pathways of
biotransformation by gut microbiome includes dehydroxylation, demethoxylation and
demethylation, and isomerization.

2.3 Polymethoxyflavones (PMFs)

2.3.1 Chemistry of PMFs

Polymethoxyflavones are a group of unique flavonoids found almost exclusively in citrus
fruits (sweet oranges and mandarin oranges), especially in their peels.
PMFs contain two or more methoxyl groups on their basic C6-C3-C6 skeleton with a carbonyl
group at the C4 position [24]. They have been increasingly associated with health benefits,
including protection against cancer, cardiovascular disease, inflammatory disorders, viral
infections, diabetes and neurological conditions. The structures of major polymethoxyflavones
are shown in Figure 2.2. 5-hydroxy-6,7,8,3’,4’-pentamethoxyflavone, or 5-demethynobiletin (5DN) and 5-hydroxy-6,7,8,4’-tetramethyoxyflavone or 5-demethytangeritin are the PMFs
generated during the aging process [25].
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There are many reports on the biological activities, biotransformtations of NBT.
However, 5-DN is a PMF found in aging citrus peels. Only a few reports were focused on 5-DN
to date.

Figure 2.3 Chemical structures of polymethoxyflavones (PMFs). A) Nobiletin (NBT), B) 5hydroxy-6,7,8,3’,4’-pentamethoxyflavone, or 5-demethynobiletin (5-DN) C) Tangeretin(TAN)
D) 5-hydroxy-6,7,8,4’-tetramethyoxyflavone or 5-demethytangeritin
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Figure 2.4 HPLC chromatographs of peels from tangerine and sweet orange (Adopted from Li
Shiming and et al. )

2.3.2 Bioavailability of PMFs

2.3.2.1 Current studies of PMFs oral bioavailability

There are three rodent studies investigating the tissue distribution and bioavailability of
nobiletin after to date. In the first study, after the oral administration of Si-Ni-San (SNS), a
Chinese medicine containing multiple polymethoxyflavones including nobiletin (dosage
0.427mg/kg), the concentration in plasma, liver, brain and spleen was 12ng/mL (29.8nmol/g),

15

44.5ng/mL (110nmol/g), 27.2ng/mL (67.4nmol/g) and 77.8ng/mL(194nmol/g) correspondingly
[26].
In the second study, after the oral administration of 50mg/kg NBT to male S.D. rats, the
plasma level can reach as high as 1.78µg/Ml (4.43µM), and the brain level was 4.2µg mL
(10.4µM). The nobiletin concentration in the liver and kidneys ranged from 2 to 6µM [27]. The
third study suggested that after given gastric intubation of nobiletin at the dosage of 67.1µmol/kg
body weight to male SD rats, stomach mucosa can reach 110nmol/g, small intestine mucosa level
was 65 nmol/g large intestine mucosa level was 4nmol/g. The concentration in liver and kidney
was 5nmol/g and 2nmol/g [28].

2.3.2.2 Methylated structure and bioavailability

Studies have shown that polymethoxylated flavonoids has improved bioavailability
compared with polyhydroxylated flavonoids. The experiment was implemented by the coadministration of nobiletin and luteolin. The former is methylated flavonoid while the latter is a
hydroxylated flavonoid. After the oral administration at the same dosage, nobiletin was found
more concentrated in liver and kidney, and a tendency of nobiletin to localize into mucosa was
observed [29].
Another interesting fact of PMFs is their high brain level. Studies have proved that most
notably in the brain, the levels of methylflavones are significantly higher than their unmethylated
analog [30].
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2.3.3 Biotransformation of PMFs

2.3.3.1 Metabolism pathway of PMFs

Demethylation of PMFs is the major metabolic pathway PMFs. By incubation of
methylated flavonoids with rat liver S9 mix, the demethylated analog was produced. The
oxidation is catalyzed by P-450 enzymes CYP1A1, CYP1A2, producing 3’- demethylation and
4’-demethylation products. 6- and 7-O-demethylations is promoted mainly by CYP3A4 [31].
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Figure 2.5 The metabolism pathway and the transportation of PMFs (Adopted from Bohn, et al. )

Nobiletin was found to undergo extensive biotransformation after oral administration.
The resultant metabolites were reported to possess different biological activities [32]. The major
metabolic pathway of nobiletin is demethylation, followed by sulfation and glucuronidation.
Studies have indicated that polymethoxyflavones are more resistant to metabolism
compared with hydroxylated flavones [33]. The 5, 7 position of PMFs are relatively stable than
the other positions. Some other studies also reported that the existence of PMFs can stimulate the
hydroxylation of benzo[α]pyrene [34]. The expression of metabolism enzymes P-450 can be
stimulated by PMFs.
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The identified metabolites are shown in figure 2.6, 3’-demethylnobiletin is the major
metabolite after incubation of nobiletin with rat liver S-9 mixture [35] as well as in the serum of
SD rats after oral administration of nobiletin. In the contrast, another study suggested that 4’demethylnobiletin was identified as the dominant metabolite from the urine [36]. 3’demethylnobiletin, 4’-demethylnobiletin, and 3’, 4’-di-demethylnobiletin was found in rat
biofluids [37]. 6-, 7- and 4’-demethylnobiletin with a relative ratio of 1:8.2:2.8 were determined
in human liver microsomes. Overall, CYP3A4 is associated with the generation of 7demethylnobiletin and CYP1A1, CYP1A2 and CYP1B1 catalyzed the formation of 4’demethylnobiletin [32]. Sulfation and glucuronidation of the metabolites are also detected in the
nobiletin biotransformation.

Figure 2.6 Structures of nobiletin and its major identified metabolites (Adopted from Li et al,
Chemistry and bioactivity of nobiletin and its metabolites.)
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2.3.3.2 Metabolites of PMFs

Demethylated PMFs are generally considered to possess higher biological activities. In
our previous studies, 5-hydroxylated PMFs were proved to show higher activities on colon cancer
cells than their methylated counterparts [38]. 3’-demethylnobiletin, 4’-demethylnobiletin, and 3’,
4’-di-demethylnobiletin were reported to have higher inhibition properties against colon
carcinogenesis than nobiletin parent compound [39].
Although 5-demethylnobiletin (5-DN) is not as abundant as nobiletin in nature, the
bioactivities of 5-DN is superior to their methylated analogs in the inhibition of cancer [38]. In
our previous study, we have identified three in vivo metabolites after the gavage administration to
mice, namely 5,3′-didemethylnobiletin, 5,4′ -didemethylnobiletin, and 5,3′4′-tridemethylnobiletin.
Major The glucuronides and sulfates metabolites were also found in tissues with high
concentration in urine [25]. The structure of major metabolites of nobiletin (NBT), 5demehylnobiletin (5DN) and tangeretin (TAN) is shown in figure 2.7.
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Figure 2.7 The structure of major metabolites of nobiletin (NBT), 5-demehylnobiletin (5-DN)
and tangeretin (TAN)
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CHAPTER 3
11.THE TISSUE DISTRIBUTION OF POLYMETHOXYFLAVONE AND ITS MAJOR
METABOLITES

3.1 Introduction

Nobiletin(NBT), or 5,6,7,8,3’,4’-hexamethoxyflavone (figure 3.1) is one of the
polymethoxylated flavonoids found exclusively in citrus fruits [40], being widely used in
traditional Chinese herbal medicines. A number of studies have shown that NBT processes
extensive pharmacological properties such as anti-proliferative[41-44], anti-inflammatory[45, 46]
anti-dementia, and anti-angiogenic activities etc.
Among all the pharmacological activities of nobiletin, anti-proliferative activity is the most
widely studied. Evidence suggested that nobiletin is efficient in inhibiting cell adhesion, invasion,
and migration abilities on brain cancer cell[47], lung cancer cells[48], breast cancer cells[49],
gastric adenocarcinoma AGS cells[42, 50], fibrosarcoma cells[51], and inducing apoptosis in
cervical carcinoma cell[52]. From the in vivo studies, nobiletin also showed significant antiproliferation and apoptosis activities on mice prostate and colon carcinogenic, and lung
carcinogenesis[48, 53, 54]. As for anti-inflammatory activities, most studies about of nobiletin
were conducted on synovial fibroblasts. It has been demonstrated that nobiletin is effective in
inhibiting inflammation on human fibrosarcoma cells[55] and promyelocyte cells[56]. More
studies proved nobiletin is a bioactive agent in interfering with ADAMTS-4 and -5 mRNA,
proMMP-9, and COX-2 mRNA expressions and PGE2 production, decrease of proliferation in
cultured human synovial ﬁbroblasts, thus preventing cartilage destruction in arthritic diseases[57,
58]. In addition, an in vivo study on mouse after i.p. administration of NBT also showed decrease
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of aggrecan in cartilage, and reduction of ADAMTS-4 and -5 mRNA expressions in joint
tissues[57]. Besides, a few groups dedicated in finding the neurotropic function of NBT in the
central nervous system, and proved that NBT improve the memory and learning impairment in
mouse model and may prevent Alzheimer’s disease [59-61]. Moreover, a number of studies have
shown that nobiletin has anti-angiogenic activities. In a model of zebrafish embryos, nobiletin
showed cytostatic effect and may also prevent worsen of heart failure[62, 63]. Taken together,
NBT, although not abundant in citrus fruits, is a promising candidate in chemoprevention and
reversion against many health damages.
However, despite all the studies on NBT chemopreventive properties, there are limited
reports on the tissue distribution of NBT. It is proved that nobiletin has a wide distribution and
accumulation after administration in tissues. Yumi Matsuoka’s study demonstrated the trend of
localization of nobiletin in mucous membrane and liver is significant at the first hour and at 4h
time point, nobiletin is mostly accumulated in large intestine and kidney. All nobiletin was
excreted at 24h. The serum concentration of nobiletin was 0.81±0.31μM after 1h of 67.1μmol/kg
of body weight gastric intubation administration[29]. Due to the remarkable anti-dementia
activity of nobiletin, many groups worked on the brain accumulation to find out whether nobiletin
can arrive at the target organ. Girish and colleagues found out that after1 h single oral dosing (50
mg/kg) of nobiletin, the maximum concentration showed up in plasma and brain were 1.78 and
4.20μg/mL, respectively[27]. Tohru’s group found out that nobiletin the highest concentration of
nobiletin was 0.90 mg/L and 3.6 mg/kg in the serum and brain of mice undergone the 3.6 mg/kg
p.o. administration[64]. Besides, nobiletin showed far higher adsorption and tissue accumulation
than other polymethoxyflavones as tangeretin and luteolin[29, 35, 65].
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Yet, few studies showed the tissue distribution of NBT metabolites. It is proved that NBT
has three major metabolites, i.e. N1 [66], N2[36] and N3[29]. A number of studies have shown
that the metabolites of nobiletin are mostly more potent than their parentcompound in antiproliferation[67], anti-inflammatory properties[37], anti-atherogenesis[68], and inhibiting the
expression of matrix metalloproteinase-9 in related to rheumatoid arthritis and tumor
metastasis[69]. The metabolites may be even more promising than NBT itself in preventing the
diseases studied before, and it is possible that it was the metabolites of nobiletin that made NBT
have wide spectrum of disease inhibitory effects in vivo studies.
In order to understand the effectiveness of nobiletin in different tissues, it is necessary find
out whether nobiletin can be delivered to the target tissues. It is even more important to have an
accurate quantification of accumulation of nobiletin metabolites in different tissues to prove the
effectiveness and elucidate the mechanism of nobiletin chemopreventive activities. Hence, in the
present study, for the first time, we demonstrate the tissue distribution of NBT and its metabolites
after oral administration of different dose to mice model by HPLC detection method[70].
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Figure 3.1 The structure of nobiletin(NBT) and its metabolites N1, N2 and N3
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3.2 Materials and Methods

3.2.1 Chemicals

HPLC grade acetonitrile (ACN), tetrahydrofuran (THF), trifluoroacetic acid (TFA),
methanol, ethyl acetate and analytical grade Phosphate Buffered Saline (0.1M) were purchased
from Fisher Scientific (Fairlawn, NJ, USA). Ammonium acetate was a product of EMD
Chemicals Inc. (Gibbstwon, NJ, USA). Sulfatase (type H-1, from Helix pomatia, containing
sulfatase and β-glucuronidase) was obtained from Sigma-Aldrich (Poole, Dorset, U.K.). Nobiletin
was purchased from Quality Phytochemicals LLC (Edison, NJ, US).

3.2.2 HPLC instrumentation and chromatographic conditions

The HPLC analysis was carried out on a CoulArray® HPLC system (Chelmsford, MA,
USA) consisting of a binary solvent delivery system (model 584), an auto-sampler (model 542), a
CoulArray® Multi-Channel EC detector (model 6210) and a UV detector (model 526) (Waters,
Milford, MA, USA). Instrument control and data processing were performed with CoulArray 3.06
software. Ascentis RP-Amide reversed-phase HPLC column (15cm×4.6mm id, 3μm) (Sigma–
Aldrich, MO, USA) was used. Flow rate was 1.0 mL/min. The temperature of auto sampler was
set to 4℃. The injection volume was 10 μL. The EC detector cell was set at the detecting
potentials of 100, 200, 300 and 400 mV, separately. The isocratic mobile phase for the HPLC
system consists of tetrahydrofuran, acetonitrile in ratio of 19:81 (v/v). 12.5mmol/L ammonium
acetate was added into the mobile phase. The pH was adjusted with trifluoroacetic acid to 3.00
before filtered through a 0.2-µm Millipore filter. The eluent was detected with a UV wavelength
at 326 nm.
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3.2.3 Preparation of standards

Standards of tissue calibration were prepared from stock solution of nobiletin and its
metabolites N1, N2, N3 (50mmol/ml) prepared in DMSO. Nobiletin and its metabolites were
diluted to concentrations of 0.5, 2, 5, 10µmol/L. Figure 3.2 is the HPLC graph of 5µmol/L
standard. Each standard has 4 compounds with the same concentration. Concentrations of DMSO
in samples did not exceed 2%.

3.2.4 Mice

All animals housed and all experiments performed were approved by the Institutional
Animal Care and Use Committee, University of Massachusetts, Amherst. 48 female A/J mice at
6wk of age weighing 18-20kg were purchased from Charles River Laboratories and were housed
in a temperature-controlled environment with a 12-h light/12-h dark cycle, receiving a standard
diet and water ad libitum. Mice were randomly divided into 2 groups of nobiletin enriched and
control, with 12 mice in each group. After 1-week acclimation, mice were maintained on
nobiletin enriched food. Nobiletin was mixed with semi-purified AIN93M (with15% casein
protein, Research Diets, Inc.) diet to formulate 250ppm nobiletin enriched diet. All mice were
sacrificed in after 14 weeks. Liver, spleen, brain, stomach, small intestine (cut equally into 4
parts), cecum and colon were removed immediately after blood collection. The blood samples
were centrifuged at 14,000 rpm for 2 min to collect the plasma. All samples were stored at −80°C
until the time of HPLC analysis. To eliminate the interference of digesta (food under digestion) in
stomach and feces in small intestine and cecum to the HPLC nobiletin determination,
immediately after the removal of stomach, small intestine and cecum, half of the samples were
cut open and digesta or feces were washed off with PBS. Small intestine was cut tetrasection. All
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tissues were frozen and kept over -40℃ dry ice upon removal, and were stored at -80℃ until
analysis.

3.2.5 Sample preparation

Prior to analysis, frozen serum and tissue samples were thaw on ice. The tissue was
placed into phosphate buffered saline (pH=5.00) and methanol in the ratio of 1:3:4 (w:v:v), and
then homogenized with 8 beads in each sample tube by OMNI Bead Raptor. After centrifugation
(14,000 rpm, 4℃, 2 min) (centrifuge company), 2 aliquots of the supernatant (400µL) were
removed to 1mL centrifuge tubes separately. With the samples evaporated to less than half
volume before evaporated (SAVANT speedvac system), sulfatase (20µL, 37℃ water bath 45min
before use) and PBS(20µL) was added to the 2 centrifuge tube separately, and vortex vigorously
before water bath (37℃,45min). 8 part volumes of ethyl acetate were added to each tube, vortex
thoroughly to make the nobiletin and its metabolites dissolved in the ethyl acetate layer. The top
layer of each sample containing the ethyl acetate was then removed as completely as possible,
making sure not to remove any of the aqueous layer, to a new centrifuge tube. Evaporate the ethyl
acetate to dryness. The residue was reconstituted with 150µL mobile phase (previously described
in 2.2), 50µL of which was then placed into autosampler vials for HPLC analysis. In the case of
the plasma samples, 2 aliquots of about 30µL plasma were add 20µL sulfatase and 20µL PBS
respectively before the water bath (37℃,45min). The rest process of residue was the same as the
tissue pretreatment.
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3.2.6 Statistical analysis

Data are represented as mean±SE. The statistical significance of the differences between
groups was calculated by unpaired two-tailed Student's t-test by IBM SPSS statistics 20. A value
of p < 0.05 was considered statistically significant.
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3.3 Results and discussion

Figure 3.2 HPLC chromatograph of the simultaneous determination of 5µmol/L NBT, N1, N2
and N3 standards with UV and ECD (500mV) detectors
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maintained on standard diet and NBT enriched diet for 14 weeks (102 days); B) Final liver weight
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Figure 3.4 Levels of nobiletin in A/J mice after 14 weeks of oral administration with 250ppm
NBT enriched diet.
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Figure 3.5 Levels of nobiletin and its metabolites N1, N2 and N3 (total of free form and their
glucuronide and sulfate counterparts) in A/J mice after 14 weeks of oral administration with
250ppm NBT enriched diet.
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Figure 3.6 HPLC-ECD Chromatographs of free form N1, N2 and N3 after in small intestine
samples: A) Sample without enzymatic hydrolysis B) Sample treated enzymes from Helix
pomatia (contains sulfatase and glucuronidase).
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Figure 3.7 Levels of free form and conjugated (glucuronide and sulfate) form of nobiletin
metabolites N1, N2 and N3 in tissues of A/J mice after 14 weeks oral administration with
250ppm NBT enriched diet.

3.3.1 Toxicity of nobiletin oral administration to mice

After maintained on nobiletin enriched diet (0.025 wt% in AIN93G diet) for 14 weeks, the
tissues of mice were collected and analyzed by HPLC to reveal the disposition and
biotransformation of NBT. Body weight was monitored every 10 days as an indicator of potential
toxicity of NBT. The result showed no significant decrease in body weight in NBT treated group
compared to the control group suggesting no general toxicity from dietary treatment with NBT
(Figure 3.3). The growing weight of spleen and liver is another indicator of the toxicity. From our
result, there was no difference in the weight of liver and spleen between the NBT-treated group
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and the control group. Taken together, we found no noticeable toxic effects caused by long-term
dietary NBT administration to mice.

3.3.2 Tissue distribution of nobiletin after oral administration

As shown in figure 3.4, nobiletin tended to accumulate in spleen, stomach and brain, with
the highest accumulation in stomach of 11.2nmol/g. The blood level of nobiletin was extremely
low and hard to detect. Unlike in serum, more nobiletin accumulated in peripheral tissues. In
brain, liver and spleen, the level of nobiletin was as high as 2.0nmol/g, 1.2nmol/g and 3.9nmol/g.
The trend that the level is high in stomach while low in small intestine and large intestine is in
accordant with the previous report[29].
Previously, the content of nobiletin after oral administration has been investigated by
several groups. After oral administration of a Chinese medicine Si-Ni-San to SD rats, with the
total nobiletin administration of approximately 500ppm, the tissue levels nobiletin content in
plasma, liver, brain and spleen was 0.03µM, 0.11nmol/g, 0.01nmol/g and 0.19nmol/g[26].
Another study using pure nobiletin with same rodent type showed significant different results.
The plasma and brain level reached as high as 4.4nmol/g and 10.4nmol/g after 50mg/kg nobiletin
administration[27]. Murakami’s group also reported that after gastric intubation of nobiletin of
67.1µmol/kg body weight of SD rats, the nobiletin contents in stomach mucosa, small intestine
mucosa, large intestine mucosa and liver were 110nmol/g, 65nmol/g and 4nmol/g
correspondingly[29]. The absolute values are not comparable due to mice type, delivery methods
and dosages. It is also worth mentioning that unlike the single-dose oral administration applied in
aforementioned studies, we applied long-term oral administration of nobiletin with diet for 14
weeks in the current study. With nobiletin mixed with diet, the experiment effectively mimics the
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process of obtaining nobiletin from food or dietary supplements for a long-term. In fact, our
results seem to indicate a higher level tissue accumulation of nobiletin after long-term
administration, although hydrophilic flavonoids such as quercetin and grape seeds have no
accumulation due to the long-term administration[71, 72]

3.3.3 Extensive biotransformation of nobiletin in vivo

Figure 3.5 shows the total tissue levels of N1, N2 and N3 in both free form and
conjugated form. It is obvious that the levels of nobiletin metabolites are much higher than the
parent compound in most metabolic tissues. It indicates the extensive biotransformation in vivo,
as also suggested by the high level of metabolites in serum.
However, considerable levels of parent compound can still be found in peripheral tissues
such as brain and spleen. This is due to the chemical structural characteristics. It is universal that
methylated flavonoids can accumulate in peripheral tissues better than their hydroxyl
counterparts, glucuronide and sulfate metabolites[33, 73, 74]. Due to the lipophilicity of the
methylated compounds, they can easily penetrate cell walls of intestine and peripheral tissues. By
comparison between the tissue distribution of nobiletin and luteolin, a hydroxyl counterpart of
nobiletin, after the oral administration at the same dose, significantly more nobiletin was found in
peripheral tissues than luteolin, while more luteolin were found in urine than nobiletin[29]. As far
as the high level of nobiletin accumulation in brain which is not observed in most polyphenols, it
can be attributed to the methoxyl structure. While it has been reported that quercetin also
accumulates in brain after long-term oral administration[72], a recent report suggested the
methoxylated aurone was selected as a promising drug on Alzheimer’s due to its potent bloodbrain barrier permeability[75].
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3.3.4 Phase I metabolism of nobiletin in vivo

Overall, N2 is the most abundant metabolite after oral administration and is the dominant
metabolite in GI tract tissues and liver and serum. Considerable N1 and N3 were found in cecum
and colon respectively as well. Although N1, N2 and N3 are all demethylation products of NBT,
the position and number of methyl group are different. The difference of tissue level between N1
and N2 can be ascribed to the discrimination of demethylation position between 3’ and 4’. N3, on
the other hand, is the di-demethylation product of NBT, which is also the demethylation product
of N1 and N2. The high abundance of N3 in colon tissue may reveal the strong demethylation
ability of enzymes in colon mucosa and in microbiota.

3.3.5 Phase II metabolism of nobiletin in vivo

To distinguish the free form and conjugated form of each metabolite, samples were
treated with hydrolysis enzymes (sulfatase and β-glucuronidase) for deconjugation and
determination. The chromatographs of small intestine sample before and after treated with
enzymes are shown in figure 3.6.
The levels of free form metabolites and conjugated metabolites are compared in figure
3.7. It is obvious that most metabolites in small intestine, liver and serum were in conjugated
form while most metabolites in spleen, brain, cecum and colon were in free form. The high free
form levels in spleen and brain may in part due to the chemical structural difference between
nobiletin and its demethylated and conjugated metabolites. After the demethylation and
conjugation, the compounds become more lipophobic, thus difficult to penetrate the organ surface
or blood-brain-barrier.
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On the other hand, the high free form levels in cecum and colon is very interesting when
compared with those in small intestine. Only 19.7% metabolites found in small intestine were in
free form, while 92.5% free form metabolites were found in cecum and colon. It is well
recognized that after the enterohepatic circulation, the metabolites from liver are delivered to GI
tract lumen where they will be reabsorbed by enterocytes and colonocytes. Although there may
be difference in the absorption ability between small intestine and large intestine, the relative
ratio among the different types of metabolites are expected to be consistent. The difference
between the composition of metabolites in small intestine and large intestine suggested that
cecum and colon are also important organs for the biotransformation of nobiletin, especially its
involvement in the deconjugation of nobiletin phase II metabolites. The disappearance of
conjugated metabolites in cecum/colon and the increase of the free form metabolites may indicate
the change of the physical environment (pH, water activity) or biological conditions
(microbiome) that may result in the chemical structural change of the compounds, specifically the
deconjugation and further methylation of nobiletin metabolites. Previous studies have suggested
that mammalian metabolites are subjected to the deglucuronidation by colonic microflora[22] to
generate non-polar low molecular weight metabolites. It is very likely that colonic microbiome is
the key to the biotransformation of the conjugated metabolites.

4. Conclusion

In conclusion, our result demonstrated that nobiletin underwent extensive metabolism in
vivo after long-term oral administration of nobiletin with diet. Besides, nobiletin can travel to
peripheral tissues better than its metabolites and can presumably penetrate BBB. In addition, the
4’ position is the most active demethylation site of NBT phase I metabolism in vivo. As a result,
N2 (NBT demethylated at 4’ position) is the dominate metabolites in most tissues. Furthermore,
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most nobiletin demethylated metabolites were conjugated during phase II metabolism. Last but
not the least, this study indicated the deconjugation of phase II metabolites in cecum and colon is
presumably attributed to gut microbiomes.
However, in the present study, we can neither clarify where and how nobiletin get
metabolized into the major metabolites, nor the reason for the change of metabolites composition
between small intestine and lower bowel. Although the colon is seen as an important organ for
the metabolism of nobiletin, the microbial catabolic pathways of these compounds are still under
consideration which needs further investigation. It is also noteworthy that considerable levels
novel metabolites of nobiletin were found in tissues that may also play a role in the general
bioactivity of nobiletin after oral administration. The future work of the identification and
quantification of novel metabolites of nobiletin in tissues is necessary to provide a thorough
demonstration of the tissue distribution of nobiletin metabolites.
This study is the first report of the tissue distribution of nobiletin major metabolites N1,
N2 and N3 after long-term oral administration in diet. The considerable accumulation of bioactive
metabolites in tissues may explain the biological activities of nobiletin after oral administration
even though the level of parent compound is low.
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CHAPTER 4
12.THE IN VIVO BIOTRANSFORAMTION OF POLYMETHOXYFLAVONE

4.1 Introduction

Nobiletin (NBT), a major citrus polymethoxyflavone, has been shown to have various
beneficial bioactivities such as anti-inflammatory and anti-carcinogenic effects. Recent studies
have demonstrated that the metabolites of NBT have higher bioactivities than the parent
compound. In order to elucidate the cause-effect relationship between NBT oral consumption and
it’s in vivo bioactivities, we investigated in the biotransformation of NBT along GI tract. In this
study, A/J mice were fed NBT 1000 ppm in diet for 16 weeks, and then GI tract mucosa, digesta
and liver were collected. Levels of NBT and its major metabolites i.e. N1, N2 and N3 in the
samples were determined by HPLC analysis. Our results showed that NBT underwent
demethylation and conjugation in the small intestine to glucuronide and sulfate conjugates of N1,
N2 and N3. In contrast, these conjugates were largely deconjugated in the colon presumably by
colonic microflora. It can be predicted that the overall NBT bioactivities can be enriched after
oral consumption due to its extensive in vivo biotransformation in GI tract.
Nobiletin(NBT) is the most prevalent ﬂavone exclusively existing in citrus genus,
particularly in their peels[40]. A number of studies have shown that NBT processes extensive
pharmacological properties such as anti-angiogenic, anti-proliferative[41, 42, 44, 76], antiinflammatory[45, 46] , anti-dementia activities, etc. both in vitro and in vivo.
However, in order to elucidate the whether the compounds that exerting bioactivities is
nobiletin or its metabolites, it is important to investigate the metabolism and biotransformation of
NBT in vivo. A few studies on the biotransformation of NBT have been reported. Unlike other
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polyhydroxyl phenolic compounds[77], NBT is in the form of aglycone in nature, and hydrolysis
is not involved in the biotransformation. Instead, it is proved that the major biotransformation
pathway of NBT is demethylation. N1[28], N2[36] and N3[78] are the three major metabolites
identified from rats and mice urine after oral administration. Recently, Koga et al. has reported 7OH-NBT is the major metabolite of nobiletin through in vitro incubation with human liver
microsomes[32].
Furthermore, many groups have further investigated the bioactivities of NBT metabolites
and a number of studies were focused on N1, N2 and N3 and the result have shown that these
three metabolites are more potent than their parentcompound in their in vitro and in vivo
bioactivities such as anti-cancer[67, 79], anti-inflammatory[37] and anti-oxidative properties[80],
as reviewed by Shiming Li[81].
However, there is no report on the biotransformation of NBT related with specific sites.
Therefore, in the current study, we investigated on the biotransformation of NBT after oral
administration specifically in gastrointestinal tract. We primarily focused on the
biotransformation of NBT into N1, N2 and N3 since they are the three major metabolites that
have been proved to possess higher bioactivities than NBT. This is the first report of the fate of
NBT in GI tract after oral administration in regard of the absorption and metabolism of NBT in
the small intestine, and its subsequent biotransformation in cecum colon. This study will provide
important information regarding potential bioactive components in vivo.
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4.2 Materials and Methods

4.2.1 Chemicals

HPLC grade acetonitrile, tetrahydrofuran, trifluoroacetic acid, methanol, ethyl acetate
and analytical grade Phosphate Buffered Saline (0.1M), K2HPO4, NaH2PO4, NH4Cl, cysteine
hydrochloride, DifcoTM yeast extract, pectin, nitrilotriacetate, MgSO4.7H2O, MnSO4.4H2O, NaCl,
FeSO4.7H2O, CoCl2.6H2O, CaCl2, ZnSO4.7H2O, CuSO4.5H2O, AlK(SO4)2.12H2O, H3BO3,
Na2MoO4.2H2O, NiSO4.6H2O, Na2SeO3, Na2WO4.2H2O, resazurin solution were purchased from
Fisher Scientific (Fairlawn, NJ, USA). Ammonium acetate was a product of EMD Chemicals Inc.
(Gibbstwon, NJ, USA). Sulfatase (type H-1, from Helix pomatia, containing sulfatase and βglucuronidase) Glucose-6-phosphate, NADP, Yeast glucose-6-phosphate dehydrogenase was
purchased from Sigma-Aldrich (Poole, Dorset, U.K.). Nobiletin was purchased from Quality
Phytochemicals LLC (Edison, NJ, US).

4.2.2 Rodents and Tissue collection

All animals were housed and all experiments performed were approved by the
Institutional Animal Care and Use Committee, University of Massachusetts, Amherst. 48 female
A-J mice at 6wk of age weighing 18-20kg were purchased from Charles River Laboratories and
were housed in a temperature-controlled environment with a 12-h light/12-h dark cycle, receiving
a standard diet and water ad libitum. Mice were randomly divided into 2 groups of treatment and
control, with 12 mice in each group. After one-week acclimation, mice were maintained on
nobiletin enriched food. Nobiletin was mixed with semi-purified AIN93M (with15% casein
protein, Research Diets, Inc.) diet to formulate 1000ppm nobiletin enriched diet, which were
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orally administrated to the control and NBT group correspondingly for 16 weeks. All mice were
sacrificed at 23 weeks of age. Liver and mucosa of stomach, small intestine (duodenum, jejunum
ileum partI, ileum partII), cecum and colon were removed immediately after sacrifice. Digesta
(food content) in corresponding part of GI tract lumen were also collected. All samples were
stored at −80°C until the time of HPLC analysis.

4.2.3 In vivo colonic microbiota biotransformation

Cecum microbiota inoculum preparation The mice cecum digesta was acquired from
the control group mice. The samples were suspended and homogenized into 10 mL culture
medium with 0.4 mL DMSO on the Hungate. 1 mL intestinal and fecal suspension was inoculated
into 9 mL culture medium, and anaerobically incubated at 37°C for 24 h. The anaerobic culture
medium used in this study was prepared according to the anaerobic techniques of Hungate[82].
SI digesta incubation The small intestine digesta of mice from NBT treated groups were
extracted by butanol three times. The combined butanol extracts were dried under vacuum, and
dissolved in DMSO to achieve final concentration of NBT metabolism complex of 10mmol/L –
15 mmol/L. 10 μL small intestine content stock solutions were added to 9.5 mL medium,
followed by addition of 0.5 mL of cecum microbiota inoculum. 10 μl of small intestine content
stock solution was added to 10 mL medium without colonic microbiota inoculum as positive
control. 10 μl DMSO was added to 9.5 mL medium, followed by addition of 0.5 mL of colonic
microbiota inoculum without small intestine content stock solution as negative control. The
mixture was incubated at 37°C for 24 h in COY anaerobic chamber (Grass lake, MI) containing
98% N2, 2% H2.
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4.2.4 Sample preparation

Two aliquots of tissue or fermentation samples from the control and NBT treated groups
were added into 200 μL 50% methanol to precipitate proteins. The first aliquot was incubated
with 20 μL of mixed α-D-glucuronidase (250U) and sulfatase (1U) solution at 37 °C for 45 min,
and the second aliquot was incubated with 20 μL of PBS buffer (pH=5.0) at 37 °C for 45 min.
The samples were then extracted with 400 μL of ethyl acetate for three times. The combined ethyl
acetate extracts were dried under vacuum, and dissolved in 100 μL of 50% mobile phase for
HPLC analysis.

4.2.5 HPLC Analysis

Standards of major metabolites of NBT (N1, N2, and N3) were synthesized as previously
described. Analysis of the composition of the samples was performed with CoulArray® HPLCEC-UV system (Chelmsford, MA, USA). LC-MS system. Ascentis RP-Amide reversed-phase
HPLC column (15cm×4.6mm id, 3μm) (Sigma–Aldrich, MO, USA) was used. The isocratic
mobile phase for the HPLC system consists of tetrahydrofuran, acetonitrile in ratio of 19:81 (v/v).
12.5mmol/L ammonium acetate was added into the mobile phase. The pH was adjusted with
trifluoroacetic acid to 3.00 before filtered through a 0.2-µm Millipore filter. The eluent was
detected with a UV wavelength at 326 nm.

4.2.6 Metabolic activation of NBT, N1, N2 and N3

Incubation of NBT, N1, N2 and N3 with liver S9 fraction NADPH-generating system
was prepared as previously described in Sohl’s protocol[83]. The mice S9 fraction was prepared
as following described: Frozen livers of AJ mice were acquired from the control group. The liver
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S9 fraction, which contained 250 mg liver/ml was prepared by centrifugation of whole
homogenate at 9000 × g for 20 min. The incubation mixture consisted of 75 µL NADPHgenerating system, 10 µL mice S9 fraction, 0.1 M PBS to achieve a final concentration of NBT,
N1, N2 or N3 of 25µM. The pre-incubated (37°C for 3 min) NADPH-generating system was
added to the incubation solution to start the oxidation reaction. After 2 hours at 37°C, the reaction
was quenched with 2 ml of methanol and mix with a vortex device. Three control groups were
composed of treatment only, treatment with NADPH-generating system, treatment with S9
fraction correspondingly. The extracts were taken up in 200 μl of acetonitrile was subjected to
LC-MS.

4.2.7 Analysis of NBT, N1, N2 and N3 metabolites by HPLC-MS

Liquid chromatographic separation and mass spectrometric detection were performed
using a single-quad LC–MS system (Model 2020, Shimadzu, Kyoto, Japan), which is comprised
a binary pump (20AD), vacuum degasser unit, thermostatted autosampler (SIL 20AC) and mass
analyzer (MS 2020) with both electrospray ionization (ESI) and atmospheric-pressure chemical
ionization (APCI) systems.
Optimized mass spectra were acquired with an interface voltage of 4.5 kV, a detector
voltage was set to the tuning result, a heat block temperature of 400°C and a desolvation gas
temperature of 250°C. Nitrogen was used as the nebulizer gas at a flow rate of 1.5 L/min and dry
gas flow of 12 L/min. Data acquisition and processing were accomplished using Shimadzu LCMS solution Version 3.30. Quantization was performed by selected ion monitoring (SIM), using
ESI mode for NBT ([M-H]+; m/z = 403), N1 ([M-H]+; m/z = 389), N2 ([M-H]+; m/z = 389) and
N3 ([M-H]+; m/z = 375).
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Liquid chromatographic separation was achieved on Zorbax SB-Aq C18 column (150
mm × 4.6 mm, 5 µm, Agilent Technologies, USA) fitted with Zorbax SB-Aq C18 guard column
(12.5 mm × 4.6 mm, 5 µm, Agilent Technologies, USA). Mobile phase is composed of solvent A
(95% water, 5% acetonitrile (vol/vol) and B (100% acetonitrile). The following gradient is used
with a 1 ml/min flow rate: 0 min, 10% B; 5 min, 50% B; 15 min, 70% B; 25 min, 90% B; 25.1
min, 100% B; 30 min, 100% B. Calibration curves were prepared by supplementation with
known concentrations (0.1, 0.5, 1, 5 and 10 μmol/L) of NBT, N1, N2 and N3 in the 50%
methanol in water. The correlation coefficients evaluated by linear regression analysis were 0.999
or above.

4.2.8 Statistical analysis

Data are represented as mean±SE. The statistical significance of the differences between
groups was calculated by unpaired two-tailed Student's t-test by IBM SPSS statistics 20. A value
of p < 0.05 was considered statistically significant.
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4.3 Results

Figure 4.1 Chromatograph of enzyme (β-glucuronidase, sulfatase) treated SI4 mucosa sample
Top: ECD detector, 400mV; Middle: ECD detector, 100mV; Bottom: UV detector (shown as
negative).
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Figure 4.2 Levels of NBT in mice GI tract mucosa and digesta after keeping 1000ppm NBT
enriched diet for 16 weeks.
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4.3.1 Levels of nobiletin in intestinal mucosa versus muscularis
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Figure 4.3 The levels of NBT, N1, N2, N3 and their conjugated counterparts in stomach mucosa
and muscularis of mice after oral administration of 500ppm NBT enriched diet.
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Figure 4.4 The levels of NBT, N1, N2, N3 and their conjugated counterparts in small intestine
mucosa and muscularis of mice after oral administration of 500ppm NBT enriched diet.
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Figure 4.5 The levels of NBT, N1, N2, N3 and their conjugated counterparts in cecum mucosa
and muscularis of mice after oral administration of 500ppm NBT enriched diet.
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Figure 4.6 The levels of NBT, N1, N2, N3 and their conjugated counterparts in colon mucosa
and muscularis of rats after oral administration of 500ppm NBT enriched diet.
Nobiletin is mostly found in muscularis rather than in mucosa in most of the GI tract tissues. The
levels of nobiletin in stomach mucosa were similar to those of the muscularis. Overall, the levels
of nobiletin conjugated metabolites tend to be transported to muscularis, whereas free form
metabolites are primarily found in mucosa.
The possible explanations for the tendency for free form metabolites to be found mostly in
mucosa could be the polarity difference between free form and conjugated forms. Most of the
biotransformation related enzymes cytochrome P450 is found in small bowel mucosa
(enterocytes). The result indicates the concentrated aggregation of nobiletin metabolites in small
intestine mucosa, rather than the entire gut wall.

52

4.3.2 Distribution of NBT in GI tract

Figure 4.2 shows the level of NBT in GI tract mucosa compared to digesta. In general,
the levels of NBT were higher in digesta compared to mucosa in both stomach and small
intestine. In stomach, digesta level was 19-fold higher than mucosa, while in small intestine the
difference was only 5-fold. No significant difference has been observed between NBT level in
cecum mucosa and digesta. In comparison between different parts of the GI tract, NBT levels in
both mucosa and digesta were decreasing from the proximal to distal part of GI tract with the
concentration dropping from 44±0.25nmol/g in stomach mucosa; 830±99nmol/g in stomach
digesta to 1.7±0.6nmol/g in colon mucosa;1.08±0.36nmol/g in feces. It is notable that NBT
concentrations were also different among different segments of small intestine. SI4 mucosa and
digesta level was significantly lower than first 3 segments of small intestine.
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A) N1

B) N2

C) N3
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Figure 4.7 Levels of NBT major metabolites in mice GI tract mucosa and digesta after keeping
1000ppm NBT enriched diet for 18 weeks. A) N1 free form and conjugated form; B) N2 free
form and conjugated form; C) N3 free form and conjugated form.
Figure 4.7 shows the tissue accumulation of NBT major metabolites, N1, N2, N3, both
free form and conjugated form, throughout GI tract.
In general, for all three major metabolites, the free form was predominant in stomach,
cecum and colon (up to 99% free form), while the majority form in small intestine was
conjugated form (up to 89%), both mucosa and digesta (Conjugation, Microbial metabolism). It is
notable that although not comparable to the level in distal part of GI tract, there were considerable
amount of free form metabolites accumulated in stomach mucosa and digesta, e.g. N3 stomach
digesta level was as high as 60±19nmol/g (Enterohepatic Circulation, Demethylation but not
conjugation). Interestingly, the overall N2 and N3 metabolites (free form+conjugated form)
concentration in small intestine showed a dramatic decline from SI1 to SI2, and rise gradually
from SI2 to SI4, while N1 concentration was steadily increased from SI1 to SI4. Further, unlike
N1, whose overall (free form+conjugated form) concentration was lower in cecum than in small
intestine both in mucosa and digesta, N2 and N3 (free form+conjugated form) level showed a
sharply rise from small intestine to cecum, specifically in mucosa, but not digesta. Moreover, the
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level of N3 in colon mucosa (99% in free form 25±6.6 nmol/g) was also higher than small
intestine mucosa level (14.5±2.9nmol/g), which was not seen with N1 and N2 (Demethylation).
The deposition of NBT metabolites in GI tract mucosa compared to digesta can also be
revealed from Figure 4.7. In general, both free form and conjugated form metabolites showed
higher accumulation in stomach digesta than mucosa. On the other hand, free metabolites
concentrations had seen no significance between mucosa and digesta in small intestine, while
conjugated metabolites were mostly accumulated in digesta. As for cecum, free form N2 showed
no preference of deposition, but N3 concentration in digesta was higher. It is interesting that both
free form and conjugated form N1 has even higher accumulation in cecum mucosa than in digesta
(Transportation and Demethylation). It is important to note that the levels of metabolites in colon
digesta, i.e. feces, is practically not comparable with other tissue level, as compounds got
concentrated from losing water content in colon.
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Figure 4.8 Relative ratio between NBT and its metabolites in mice GI tract mucosa and digesta
after keeping 1000ppm NBT enriched diet for 16 weeks. A) Free form metabolites; B)
Conjugated form.

Figure 4.8 shows the relative abundance of metabolites distributed in GI tract. Although
it is obvious that N2 is the predominant metabolite throughout GI tract (Demethylation), there
was an increase of N3 proportion in cecum and colon, observed both in mucosa and digesta
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(Microbial metabolism). Besides, the trend is clear that as the concentration of NBT going
downwards from the proximal to increase distal part of GI tract, the metabolites concentration
went upwards. In addition, as shown in Figure 4.8 b), there was a peak of NBT metabolites
concentration (sum of free form and conjugated form) in SI1, after the decline from SI1 to SI2,
the concentration raised steadily from SI2 to SI4 (Demethylation).

4.3.3 Distribution of NBT in liver

Figure 4.9 Level of NBT and its metabolites in mice liver after 1000ppm NBT enriched diet for
16 weeks.

The accumulation of NBT and its metabolites in liver is shown in Fig. 6. The
predominant metabolite in liver is N2. On the other hand, N1 and N3 were scarcely detected. The
metabolites in liver were largely in conjugated form.
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4.3.4 In vitro biotransformation of NBT, N1, N2 and N3 by mice liver S9
A1) NBT ([M-H]+; m/z = 403 )

A2) NBT ([M-H]+; m/z = 389)
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B1) N1 ([M-H]+; m/z = 389)
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B2) N1 ([M-H]+; m/z = 375)

C1) N2 ([M-H]+; m/z = 389)
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C2) N2 [M-H]+; m/z = 375

D1) N3 ([M-H]+; m/z = 389)
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D2) N3 ([M-H]+; m/z = 375)

Figure 4.10 Extracted LC-MS chromatogram at m/z 403(+), m/z 389(+) or m/z 375(+) of
metabolites formed by incubation of NBT, N1, N2 and N3 with mice liver S9. A concentration of
25 µM of (A) NBT, (B) N1, (C) N2 and (D) N3 was incubated with mice liver S9 fraction for 2 h
at 37°C. The control (1) panel shows one of the control groups prepared with NBT, N1, N2 or
N3, 75 µL NADPH-generating system, and 0.1 M PBS. Data from other control groups are not
shown. They are similar to the Control (1) groups. LC-MS was performed using a reversed-phase
column with monitoring at positive mode, as described in Materials and methods.
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After incubation with mice liver S9 in the presence of an NADPH-generating system,
several metabolites of NBT, including N1, N2 and N3 (Figure 4.10 A2) complete) was produced,
which were not detected in the chromatogram of the extract by incubation with the NADPHgenerating system and NBT alone (Figure 4.10 A2) control (1)). Similarly, N3 was detected after
N1 or N2 was incubated with S9 and NADPH-generating system, but not in the control groups.
Interestingly, after the incubation N3 with S9 and NADPH-generating system, N1 and N2 were
produced, yet NBT was not detectable (data not shown).
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4.3.5 In vitro biotransformation of small intestine digesta by mice microbiome
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Figure 4.11 Levels of NBT and metabolites in small intestine digesta before and after the
incubation with colonic microbiome.

In order to further investigate the influence of colonic microbiota of nobiletin in the GI
tract, the small intestine digesta was incubated with mice colonic microbiota. The free form
metabolites of N1, N2 and N3 increased significantly while none of the conjugated form
metabolites were detectable after incubation.

4.4 Discussion

Although first-pass metabolism can be eliminated by using other route of administration,
e.g. intramuscular or sublingual, it is inevitable for bioactive compound administrated orally.
Therefore, fully understanding of the biotransformation after oral consumption is necessary in
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estimation and explanation of the in vivo efficacy of NBT as nutraceuticals, dietary supplement or
simply food components.
The aim of this study is to elucidate the biotransformation of NBT in GI tract and their
underlying mechanism. We determined the accumulation of major metabolites N1, N2, N3 in GI
tract, not only the free forms but also their conjugated forms, which are primarily glucuronides
and sulfides. We demonstrated the in vivo demethylation of NBT into its major phase I
metabolites N1, N2 and N3, and the conjugation of N1, N2 and N3 into their glucuronide or
sulfate counterparts. There are other metabolites detected in both mucosa and digesta samples
too, as can be seen from SI4 mucosa chromatograph of enzyme treated sample (Figure 4.2), but
the current study only focus on N1, N2 and N3. The approach of NBT administration in this study
was by enriched diet, which is superior to other single dose or multiple dose oral administration
for mimicking the intake of NBT from daily diet. Since the distribution of NBT occurring in
natural citrus peels can be as high as 8000ppm[84], the dose of 1000ppm NBT used in this study
can reasonably represent the possible amount that one can get from diet. Though the data we
obtained was a snapshot of NBT and metabolites distribution in GI tract tissues during the long
term, it faithfully reflects the biotransformation in GI tract after long term administration.

4.4.1 Demethylation, Conjugation

We demonstrated the change of the composition of NBT and its metabolites in gastric
tract by analyzing their distribution in digesta of different segments of GI tract. Despite the high
concentration of NBT and all metabolites in the first segment of small intestine, the overall (free
form and conjugated form) and conjugated form concentration of N2 and N3 were growing while
the concentration of NBT dropping from the second segment of small intestine to the fourth
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segment of small intestine reveals the fact that besides recycled from enterohepatic circulation,
demethylated and conjugated metabolites also produced in small intestine.
Interestingly, metabolites also appeared in stomach mucosa and digesta. Since there is no
interference of enterohepatic circulation, the accumulation of free form metabolites in stomach
may indicate the demethylation, but not conjugation, potential of stomach mucosa.
The in vivo activities of different types of NBT metabolites formation are different.
According to the result, N1 was not abundant in small intestine, and no significant increase of N1
accumulation was observed along small intestine, suggesting that 3’ position is not the major
target of demethylation in liver or in small intestine. Rather, 4’ position is more active in
demethylation in liver and small intestine, as N2 was the major metabolite with increased
accumulation in GI tract. The conflict with previous reports claiming conjugated N1 was the
major metabolite in mice or rat urine[29] suggests that other metabolism organ may also involve
in the biotransformation of NBT.
Despite extensive conjugation, NBT has been largely transformed in vivo into its
demethylated metabolites. We employed an in vitro S9 metabolism method to elucidate the role
of liver on NBT biotransformation. The result indicated that NBT can be metabolized into N1, N2
and N3 liver. N1 and N2 can be further demethylated into N3. Reversely, N3 can also be
methylated in liver into N1 and N2. The concentration of the NBT metabolites detected in GI
tract is the equilibrium of the methylation and demethylation mechanism of liver. Other
metabolites, other than N1, N2 and N3, were formed by S9 in vitro metabolism, are presumably
7-OH, 4’-OH and 6-OH nobiletin as proved by in vitro metabolism of NBT by liver microsomes
in other groups[32]. Even though 7-OH and 6-OH nobiletin accumulation was not determined in
the present study, the result of high 4’-OH (N2) accumulation in liver is in agreement with the in
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vitro study. As N2 was also the major metabolite throughout GI tract, it is possible that the major
biotransformation site is liver, rather than small intestine. Yet, the reactions in GI tract mucosa
also played an important role in the biotransformation of NBT, as discussed above, into
metabolites N1, N2 and N3, which have been proved to possess higher bioactivities than NBT.
Particularly, with low accumulation in SI1, N1 was produced increasingly from SI1 to SI4
suggesting that little N1 came from enterohepatic circulation, and most of N1 was produced in
small intestine rather than in liver. Therefore, we can conclude that the biotransformation in GI
tract mucosa, especially in ileum and cecum mucosa activated NBT pharmacological properties.

4.4.2 Microbial biotransformation

Glucurono- and sulfo-conjugated metabolites are the predominant forms of metabolite for
most flavonoids in GI tract[85]. It is widely known that gut microbiota may produce βglucuronidase that is responsible for deconjugation for glucuronides[86].
Based on the result obtained with free form metabolites and conjugated metabolites in small
intestine and large intestine, we considered that conjugated NBT metabolites may also get
deconjugated by microbiota. To test this idea, we conducted an in vivo microbial test to incubate
the digesta of small intestine of mice maintained on NBT enriched diet with inoculates cultured
from colonic microbes obtained from mice administrated with standard diet. Our result that
conjugated NBT metabolites get transformed into free form by colonic microbes for the first time
reveals deconjugation potential of microbiota for polymethoxyflavone metabolites. Furthermore,
the increased accumulation of N3 in large intestine, especially in colon, and the larger proportion
of N3 in feces compared to other segments of GI tract digesta indicate tremendous N3 production
in colon, presumably through microbial metabolism. This finding is in agreement with previous
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report proving microbial hydroxylation on 3’ and 4’ position on flavones[87]. It is also possible
that NBT get decomposed into other single ring molecules by microbial metabolism, but no
evidence available from the current study.
Due to the deconjugation of microbiota, higher level of free form metabolites
accumulated in cecum mucosa and colon mucosa. From our previous study, conjugated
metabolites barely show any bioactivity on colonic cancer cell growth, hence, free form is the
only activated form to exert bioactivities. Therefore, the deconjugation in cecum and colon is
very important in increasing the level of activated metabolites, thus activating of NBT in vivo.

4.4.3 Transportation

The profile of NBT distribution in GI tract indicates that NBT were profoundly absorbed
into mucosa from digesta. Although the NBT level in stomach mucosa is higher than small
intestine, as also report by Matsuoka’s group in investigation of nobiletin accumulation and its
pharmacokinetics in rat GI tract after gastric intubation[29], our result reveals that NBT
absorption was more extensive in small intestine than in stomach as the difference between NBT
digesta and mucosa level was reduced to 5-fold in small intestine from 19-fold in stomach. The
mechanism could be explained by previous study by Yasufumi and colleagues suggesting that
NBT transportation in small intestine is mediated by MDR1 P-glycoprotein (P-gp) and multidrug
resistance protein 2 (MRP2) [88], a study by Tetsuya group also suggested the carrier-mediated
transportation of NBT in gastric tract[89]. However, the distribution and transportation of NBT
metabolites are not reported to date. From our result, we found that conjugated metabolites
localized in digesta, while free form metabolites showed no distribution difference between
mucosa and digesta in small intestine. (Conjugated metabolites were trapped in digesta while free
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form metabolites reach a concentration equilibrium between digesta and mucosa). This conflict
can be explained by better absorption of demethylated metabolites than their conjugated
counterparts in small intestine, which may be facilitated by free form-specific transporters in
small intestine mucosa, with the evidence that the increased N1 absorption into mucosa once
exposed to higher concentration of free form N1 in cecum digesta when compared with small
intestine. It can also be explained by the assumption that demethylation of nobiletin in small
intestine mucosa is more extensive than conjugation, which counteracts the high concentration of
the conjugated form. This assumption can be evidenced by previous study suggesting greater
demethylation ability of small intestine compared to liver[90]. Since scarce information on
conjugates transportation in small intestine in vivo is available, the results from this study also
provide valuable information of glucuronide and sulfate transportation in GI tract.
In conclusion, our study revealed the fate of NBT in GI tract after long term dietary
intake. Besides liver, GI tract mucosa including stomach, can also produce demethylated and
conjugated metabolites of NBT. NBT can be metabolized into N1, N2 and N3 in liver. N1 and N2
can be demethylated into N3, N3 can be reversely methylated into N1 and N2 in liver. The
biotransformation activities were observed more extensively in ileum and cecum than duodenum
and jejunum. We speculate GI tract mucosa have higher ability to produce N1 than liver.
Conjugated N2 were the major metabolites throughout GI tract, while microbiota in cecum and
colon can deconjugate metabolites and further demethylated NBT and metabolites. The
absorption of NBT and metabolites are more extensive in small intestine than in stomach, and
free form metabolites can be better absorbed than conjugated form presumably through carriermediated transportation. Overall, after oral administration, the bioactivity of NBT can be enriched
through in vivo metabolism of which GI tract biotransformation played a crucial role.
Tremendous enhancement occurred in cecum and colon largely due to the microbial metabolism,
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which result in high bioactivities of oral administrated NBT particularly for colonic diseases.
Further studies can focus on the bioactivities of NBT metabolites on colonic diseases in vitro and
in vivo. The contribution of small intestine in the demethylation and conjugation of NBT also
need to be addressed. We propose an in vivo metabolic pathway of nobiletin in GI tract (Figure
4.12 and 4.13)
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Figure 4.12 Summary of the NBT biotransformation in GI tract after oral administration
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Figure 4.13 Schematic diagram of proposed The in vivo metabolism of NBT in mice
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CHAPTER 5
13.TISSUE DISTRIBUTION AND BIOTRANSFORMATION OF NOBILETIN IN
DIFFERENT RODENT TYPES

5.1 Introduction

In chapter 3, we demonstrated the tissue distribution of NBT in A/J female mice after
orally administrated with NBT enriched diet. In chapter 4, we demonstrated the biotransformation
of NBT orally administrated with NBT. Although now we have a complete profile of nobiletin in
vivo distribution and metabolism after oral administration, it is still unpredictable whether the
similar pattern will also apply to other species. It is necessary to elucidate the similarities and
unique patterns of NBT tissue distribution and metabolism across rodents commonly used for
experiments. The results will be important in translation of the results from one animal model to
another and explanation of the bioactivity studies using different animal models. Furthermore, it
will also provide valuable information for the prediction of biotransformation profiles in other
mammals such as human.
CD-1 mice and F344 rats are strains commonly used in carcinogenic studies[91]. A/J
mice are typically used in lung adenoma model[92-94]. Characterization of the tissue distribution
and biotransformation in these featured strains will be a representative demonstration of PMF
ADME in rodents. This information will be particularly valuable in animal studies of
carcinogenesis.
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5.2 Materials and methods

5.2.1 Chemicals and rodents

HPLC grade acetonitrile (ACN), tetrahydrofuran (THF), trifluoroacetic acid (TFA),
methanol, ethyl acetate and analytical grade Phosphate Buffered Saline (0.1M) were purchased
from Fisher Scientific (Fairlawn, NJ, USA). Ammonium acetate was a product of EMD
Chemicals Inc. (Gibbstwon, NJ, USA). Sulfatase (type H-1, from Helix pomatia, containing
sulfatase and β-glucuronidase) was obtained from Sigma-Aldrich (Poole, Dorset, U.K.). Nobiletin
was purchased from Quality Phytochemicals LLC (Edison, NJ, US). All animals housed and all
experiments performed were approved by the Institutional Animal Care and Use Committee,
University of Massachusetts, Amherst. 12 female A/J mice, 12 CD-1 male mice and 12 F344
male rats were purchased from Charles River Laboratories and were housed in a temperaturecontrolled environment with a 12-h light/12-h dark cycle, receiving a standard diet and water ad
libitum. Rodents were randomly divided into 2 groups of nobiletin enriched and control, with 6
mice in each group. After 1-week acclimation, mice were maintained on nobiletin enriched food.
Nobiletin was mixed with semi-purified AIN93M (with15% casein protein, Research Diets, Inc.)
diet to formulate 500ppm nobiletin enriched diet.

5.2.2 HPLC instrumentation and chromatographic conditions

The HPLC analysis was carried out on a CoulArray® HPLC system (Chelmsford, MA,
USA) consisting of a binary solvent delivery system (model 584), an auto-sampler (model 542), a
CoulArray® Multi-Channel EC detector (model 6210) and a UV detector (model 526) (Waters,
Milford, MA, USA). Instrument control and data processing were performed with CoulArray 3.06
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software. Ascentis RP-Amide reversed-phase HPLC column (15cm×4.6mm id, 3μm) (Sigma–
Aldrich, MO, USA) was used. Flow rate was 1.0 mL/min. The temperature of auto sampler was
set to 4℃. The injection volume was 10 μL. The EC detector cell was set at the detecting
potentials of 100, 200, 300 and 400 mV, separately. The isocratic mobile phase for the HPLC
system consists of tetrahydrofuran, acetonitrile in ratio of 19:81 (v/v). 12.5mmol/L ammonium
acetate was added into the mobile phase. The pH was adjusted with trifluoroacetic acid to 3.00
before filtered through a 0.2-µm Millipore filter. The eluent was detected with a UV wavelength
at 326 nm.

5.2.3 Preparation of standards

Standards of tissue calibration were prepared from stock solution of nobiletin and its
metabolites N1, N2, N3 (50mmol/ml) prepared in DMSO. Nobiletin and its metabolites were
diluted to concentrations of 0.5, 2, 5, 10µmol/L. Each standard has 4 compounds with the same
concentration. Concentrations of DMSO in samples did not exceed 1%.

5.2.4 Sample preparation

All mice were sacrificed in after 14 weeks. Liver, spleen, brain, stomach, small intestine
(cut equally into 4 parts), cecum and colon were removed immediately after blood collection. The
blood samples were centrifuged at 14,000 rpm for 2 min to collect the plasma. All samples were
stored at −80°C until the time of HPLC analysis. To eliminate the interference of digesta (food
under digestion) in stomach and feces in small intestine and cecum to the HPLC nobiletin
determination, immediately after the removal of stomach, small intestine and cecum, half of the
samples were cut open and digesta or feces were washed off with PBS. Small intestine was cut
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tetrasection. All tissues were frozen and kept over -40℃ dry ice upon removal, and were stored at
-80℃ until analysis.
Prior to analysis, frozen serum and tissue samples were thaw on ice. The tissue was
placed into phosphate buffered saline (pH=5.00) and methanol in the ratio of 1:3:4 (w:v:v), and
then homogenized with 8 beads in each sample tube by OMNI Bead Ruptor. After centrifugation
(14,000 rpm, 4℃, 2 min) (centrifuge company), 2 aliquots of the supernatant (400µL) were
removed to 1mL centrifuge tubes separately. With the samples evaporated to less than half
volume before evaporated (SAVANT speedvac system), sulfatase (20µL, 37℃ water bath 45min
before use) and PBS(20µL) was added to the 2 centrifuge tube separately, and vortex vigorously
before water bath (37℃,45min). 8 part volumes of ethyl acetate were added to each tube, vortex
thoroughly to make the nobiletin and its metabolites dissolved in the ethyl acetate layer. The top
layer of each sample containing the ethyl acetate was then removed as completely as possible,
making sure not to remove any of the aqueous layer, to a new centrifuge tube. Evaporate the ethyl
acetate to dryness. The residue was reconstituted with 150µL mobile phase (previously described
in 2.2), 50µL of which was then placed into autosampler vials for HPLC analysis. In the case of
the plasma samples, 2 aliquots of about 30µL plasma were add 20µL sulfatase and 20µL PBS
respectively before the water bath (37℃,45min). The rest process of residue was the same as the
tissue pretreatment.

5.2.5 Statistical analysis

Data are represented as mean±SE. The statistical significance of the differences between
groups was calculated by unpaired two-tailed Student's t-test by IBM SPSS statistics 20. A value
of p < 0.05 was considered statistically significant.
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5.3 Results and Discussion

Figure 5.1 The levels of nobiletin in GI tract tissues and digesta of rodents (A/J mice, CD-1 Mice
and F344 Rats) maintained on 500ppm nobiletin enriched diet for 14 weeks.

We demonstrated the tissue distribution of nobiletin and its metabolites in A/J mice in
chapter 3. In order to know whether there are differences across the species, we now compare the
tissue distribution of nobiletin and its metabolites of three different rodents, i.e. A/J mice, CD-1
mice and F344 rats after oral administration of nobiletin contained diet at the same dose
(500ppm).
As shown in figure 5.1, nobiletin distribution in GI tract tissues are slightly different
across the rodent types. However, the all of them showed high accumulation nobiletin in stomach
mucosa as well as digesta, the same as previously observed in A/J mice administrated with
1000ppm.
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Figure 5.2 The levels of N1 in GI tract tissues and digesta of rodents (A/J mice, CD-1 Mice and
F344 Rats) maintained on 500ppm nobiletin enriched diet for 14 weeks.
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Figure 5.3 The levels of N2 in GI tract tissues and digesta of rodents (A/J mice, CD-1 Mice and
F344 Rats) maintained on 500ppm nobiletin enriched diet for 14 weeks.
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Figure 5.4 The levels of N3 in GI tract tissues and digesta of rodents (A/J mice, CD-1 Mice and
Rats) maintained on 500ppm nobiletin enriched diet for 14 weeks.

Figure 5.2, 5.3 and 5.4 shows the levels of nobiletin metabolites N1, N2, N3 as well as
their conjugated counterparts in three different rodents, i.e. A/J mice, CD-1 mice and F344 rats
after oral administration of nobiletin contained diet at the same dose (500ppm). Similar to what
has been observed from the previous study, for all types of rodents, N2 is the most abundant
metabolite among all three major metabolites. N2 fecal level in rats can reach as high as over
2000nmol/g.
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However, there are differences in the levels of metabolism across the species. For
instance, F344 rats has the highest N1 accumulation in most GI tract tissues and digesta. This
indicates that F344 rats may produce more 3’ position specific demethylation enzymes than A/J
and CD-1 mice.
The result from Figure 5.3 shows that N2 has higher accumulation in GI tract mucosa of
CD-1 mice than others, indicating CD-1 mice may produce more 4’ position specific
demethylation enzymes, most likely from SI mucosa, than A/J and F344 rats. It is also
noteworthy that N2 level in rat feces is higher than that found in A/J and CD-1 mice. Yet, no
significant difference of N2 level in colon tissue was observed. This may due to the limited
transportation of N2 in colon mucosa.
When compare the N3 accumulation, we noticed that CD-1 mice have higher levels of
N3 in cecum and feces. This may indicate that CD-1 mice can produce microbiome that generates
more demethylation enzymes than A/J mice and F344 rats.
As we demonstrated in Chapter 3, microbiome may produce enzymes that catalyze the
demethylation of N1 and N2 further into N3. In this study, however, we found that although N2
fecal level of rat F344 was the highest among the three types, the N3 level is not the highest. This
suggests that the microbiome of F344 rats may not produce as much demethylation enzymes
compared to A/J and CD-1 mice.
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Figure 5.5 The levels of NBT, N1, N2 and N3 in liver and serum of rodents (A/J mice, CD-1
Mice and Rats) maintained on 500ppm nobiletin enriched diet for 14 weeks.

In order to demonstrate the distribution of NBT and its metabolites in peripheral tissues,
we determined the levels in serum, liver, spleen and brain (Figure 5.5, Table 2). No significant
difference of NBT and metabolites level in liver was found among the three types. There are
considerable levels of NBT parentcompound were found in serum for of mice. In rat serum, the
levels of NBT and metabolites are hardly detectable. Yet, there is an unknown metabolite at
retention time 8.69min was found in all serum samples, the chromatogram was shown in figure
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5.6. In fact, there are other unknown metabolites also found in feces (figure 5.7) and other tissues
(figure 5.8) of all three types of rodents. This may indicate the extensive metabolism of NBT after
oral administration in rodents. These unknown metabolites may also possess bioactivities and
more investigations into that is another interesting project.

A)

B)

Figure 5.6 Chromatograph of serum of F344 rats orally administrated with 500ppm nobiletin
enriched diet by HPLC-ECD detector 400mV. Nobiletin not shown. A) Standards; B) Serum
sample
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A)

B)

Figure 5.7 Chromatograph of feces of rodents orally administrated with 500ppm nobiletin
enriched diet by HPLC-ECD detector 400mV. A) CD-1 mice; B) A/J mice
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Figure 5.8 Chromatograph of tissue samples of AJ mice orally administrated with 500ppm
nobiletin enriched diet. (A) Liver sample; (B) Enzyme (β-glucuronidase, sulfatase) treated liver
sample; (C) Colon sample a: N1, b: N2. Top: ECD detector, 600mV. Nobiletin not shown.
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5.4 Conclusion

The NBT metabolism after long-term dietary administration of NBT are similar among
the three rodent types investigated, i.e. A/J, CD-1 mice and F344 rats. The similarities are: 1.
NBT underwent extensive metabolism and only small portion can be found in feces. 2. N2 is the
major in vivo metabolite of NBT. 3. Most of conjugated metabolites were deconjugated in cecum
and colon.
However, there are some minor differences of metabolism pattern among the three rodent types
mainly shown as the relative concentration of specific metabolites accumulated in certain tissues.
From this study, we understand that it is necessary to investigate the tissue distribution
and biotransformation of oral administrated bioactive compounds for there are difference of
absorption metabolism across the species. It is most likely that there are even more tremendous
differences of metabolism pattern between rodents and human beings. Therefore, translating the
conclusion drawn from animal studies to human need to be more cautious.
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14.CHAPTER 6
15.EFFECTS OF COLONIC METABOLITES OF POLYMETHOXYFLAVONES ON
COLORECTAL CANCER AND INFLAMMATION

6.1 Introduction
Nobiletin(NBT), is the most prevalent ﬂavone exclusively existing in citrus genus,
particularly in their peels [40]. NBT have long been characterized as anti-angiogenic, antiproliferative [41, 42, 44, 76], anti-inflammatory [45, 46], anti-dementia agent.
The regular consumption of flavonoids in the human diet has been associated with
beneficial health effects on the inhibition of chronic diseases [95]. Beneficial effects of dietary
flavonoids depend on both the amount consumed and their bioavailability. One of the major
factors that limit the bioavailability is the extensive metabolism. Although first-pass metabolism
can be eliminated by using other route of administration, e.g. intramuscular or sublingual, it is
inevitable for bioactive compound administrated orally. Therefore, fully understanding of the
biotransformation after oral consumption is necessary in estimation and explanation of the in vivo
efficacy of nutraceuticals, dietary supplement or food components. As a unique group of
flavonoids, polymethoxyflavones are believed to possess higher transportation ability and
stronger resistance to biotransformation than the flavonoids with hydroxyl groups [33]. However,
our previous studies suggested that although considerable amount of nobiletin can be found in
tissues after oral administration, NBT is still subjected extensive biotransformation[24, 96].
Many groups have further investigated the bioactivities of NBT metabolites and a number
of studies were focused on three major metabolites of nobiletin, i.e. 3'-hydroxylnobiletin (N1), 4'hydroxylnobiletin (N2) and 3',4'-dihydroxylnobiletin (N3). Studies have shown that these 3

88

metabolites are more potent than their parentcompound in their in vitro and in vivo bioactivities
such as anti-cancer [67, 79], anti-inflammatory [37] and anti-oxidative properties [80], as
reviewed by Shiming Li [81].
It has been previously reported that the demethylated metabolites of polymethoxyflavone
processes strong biological activities. In our recent publication, we proposed that at least a part of
the biological activities of oral administrated nobiletin is ascribed to their colonic metabolites.
These metabolites have also been found in the most of the tissues, as demonstrated in the
previous chapters. It is very interesting to notice the high level metabolites in gastrointestinal tract
tissues. It is proposed that at least a part of the biological activities ascribed to nobiletin on colon
cancer is due to its colonic catabolites. Therefore, in the current study, we are aiming at
investigation of biological effects on gastrointestinal diseases of nobiletin after oral
administration.
To identify the active compounds responsible for the biological effects of orally
administered nobiletin in the colon, we quantified nobiletin and its major metabolites in the
colonic tissue and feces of the CD-1 male mice fed with nobiletin (0.01% in the diet for 9 weeks).
Our results showed that nobiletin and its three major metabolites, i.e. 3'-hydroxylnobiletin (N1),
4'-hydroxylnobiletin (N2) and 3',4'-dihydroxylnobiletin (N3), were detected in the colonic tissue.
However, the relative abundance of nobiletin was much lower than that of the metabolites, with
nobiletin accounted for only about 5%, and N1, N2, and N3 together accounted for about 95%.
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6.2 Materials and methods

6.2.1 Animals, diets and experimental procedure

All animals housed and all experiments performed were approved by the Institutional
Animal Care and Use Committee, University of Massachusetts, Amherst. CD-1 male mice at 6wk
of age will be purchased from Charles River Laboratories and were housed in a temperaturecontrolled environment with a 12-h light/12-h dark cycle, receiving a standard diet and water ad
libitum. Mice were randomly divided into 2 groups of nobiletin treatment and control, with 12
mice in each group. After 1-week acclimation, mice in nobiletin group were maintained on
nobiletin enriched food. Nobiletin was mixed with semi-purified AIN93M (with15% casein
protein, Research Diets, Inc.) diet to formulate 500ppm nobiletin enriched diet, which were orally
administrated to the control and nobiletin group correspondingly for 9 weeks. All feces will be
collected from bedding every week.

6.2.2 Nobiletin fecal metabolites isolation from feces

After feces samples will be acquired from the all cages of mice bedding. Two aliquots of
feces samples from the control and NBT treated groups were added into 200 μL 50% methanol to
precipitate proteins. The first aliquot was incubated with 20 μL of mixed α-D-glucuronidase (250
U) and sulfatase (1 U) solution at 37 °C for 45 min, and the second aliquot was incubated with 20
μL of PBS buffer (pH=5.0) at 37 °C for 45 min. The samples were then extracted with 400 μL of
ethyl acetate for three times. The combined ethyl acetate extracts were dried under vacuum, and
dissolved in 100 μL of 50% mobile phase for HPLC analysis.

90

6.2.3 Determination of fecal levels of NBT and its metabolites by HPLC

Standards of major metabolites of NBT (N1, N2, and N3) were synthesized as previously
described. Analysis of the composition of the samples was performed with CoulArray® HPLCEC-UV system (Chelmsford, MA, USA). LC-MS system. Ascentis RP-Amide reversed-phase
HPLC column (15cm×4.6mm id, 3μm) (Sigma–Aldrich, MO, USA) was used. The isocratic
mobile phase for the HPLC system consists of tetrahydrofuran, acetonitrile in ratio of 19:81 (v/v).
12.5mmol/L ammonium acetate was added into the mobile phase. The pH was adjusted with
trifluoroacetic acid to 3.00 before filtered through a 0.2-µm Millipore filter. The eluent was
detected with a UV wavelength at 326 nm.

Figure 6.1 Chromatograph of simultaneous determination of NBT, N1, N2 and N3 by HPLCECD-UV. NBT was detected by UV; N1, N2 and N3 was detected by electrochemical detector.
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6.2.4 Fecal isolates extraction

Feces will be homogenized with PBS and methanol. Major PMFs and their corresponding
metabolites in the samples were extracted with ethyl acetate. After evaporation under vacuum,
residues were reconstituted with mobile phase.

6.2.5 Analysis of cell viability

Assays for cell viability, cell cycle and apoptosis were conducted as we previously
described[41]. In brief, human colorectal cancer cells, HCT116 and HT29 (ATCC, Manassas,
VA, USA) were seeded in 96-well plates. After 24 h, cells were treated with serial concentrations
of NBT and its metabolites, and the cell viability was quantified by MTT method [41].

6.2.6 Cell viability and nitric oxide assay
The cell viability was determined as previously described[79]. RAW 264.7 cells (5 × 104
cells/well) were seeded in 96-well plates. After 24 h, cells were treated with 65 serial
concentrations of 4DN in 200 μL of serum complete media. After 24 h treatments, cells were
subject to MTT assay. Media were replaced by 100 μL of fresh media containing 0.1 mg/mL of
MTT (Sigma-Aldrich, St. Louis, MO, USA). After 2 h of incubation, MTT-containing media
were removed, and the reduced formazan dye was solubilized by adding 100 μL of DMSO to
each well. After gentle mixing, the absorbance was monitored at 570 nm using a plate reader
(Elx800TM absorbance microplate reader, Biotech Instrument, VT, USA). The nitrite
concentration in the culture media was measured as an indicator of NO production by the Griess
reaction. The culture media were mixed with an equal volume of Griess reagent A and B (A: 1%
sulfanilamide in 5% phosphoric acid, and B: 1000ppm naphthylethylenediaminedihydrochloride
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in water). Absorbance at 540nm was measured by a plate reader, and concentrations of nitrite
were calculated according to a standard curve constructed with sodium nitrite as a standard as we
previously reported[97].

6.2.7 Detection of Cell Cycle

HCT-116 and HT-29 cells were seeded as single cell in 6-well suspension plates in SFM
at a density of 6000 cells per well. Right after seeding, cells were treated with different
concentrations of NBT, 5-DN and their metabolites. After about 7 days, the whole content of each
well were collected by brief trypsinization (0.25% trypsin-EDTA; Sigma-Aldrich). Cell pellets
were then washed with 1mL of ice-cold PBS and then resuspended in 1mL of 70% ethanol in 20°C overnight. After centrifugation (1600g, 1 min), the supernatant was removed and cells were
incubated with 0.3mL of PBS containing 30 μg RNase (Sigma-Aldrich) and 3μg propidium
iodine (Sigma-Aldrich) for 30min at room temperature. Single-cell suspension was generated by
brief trypsinization. Cell cycle was analyzed using a BD LSR II cell analyzer at the analytical
cytometry facility (University of Massachusetts Amherst), and data was processed using Modifit
LT software.

6.2.8 Detection of apoptosis

HT-29 cells were seeded and treated exactly the same as described in cell cycle analyses
above. After 7 days of incubation, apoptotic cells were quantified by Annexin V/propidium
iodide (PI) double staining assay. Annexin V/PI staining were done using apoptotic detection kit
(BioVision, Mountain View, CA, USA) following the manufacturer’s instruction. Briefly, the
content of each well was collected and disrupted by brief trypsinization, and then washed with ice
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cold PBS. After another wash with binding buffer, cells were suspended in 0.3 mL Annexin V
binding buffer containing Annexin V and PI, and incubated for 5min at room temperature before
analysis by flow cytometer. Early apoptotic cells were identified as Annexin V-positive/PInegative cells, while late apoptotic/necrotic cells were identified as Annexin V-positive/PIpositive cells using BD LSRII cell analyzer at the analytical cytometry facility (University of
Massachusetts Amherst)

6.2.9 Quantitative RT-PCR analysis of stem cells related key proteins

Total RNA including miRNA will be isolated from parental cells, and colorectal tumor
spheres using miRNeasy mini kit (QIANGEN) for detection of transcripts for Sox2, Nanog,
Oct3/4, Notch1, Notch2, Notch3, and STAT3. cDNA of these mRNA will be synthesized and
quantitative real-time PCR will be carried out with a Strategene RT-PCR system. Experiments
will be normalized to glyceraldehyde 3-phosphate dehydrogenase (GADPH).
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6.2.10 Enzyme-linked immunosorbent assay (ELISA) and real-time qRT-PCR Analysis

HCT-116 and HT-29 scraped and homogenized in a phosphate buffer solution containing
0.4 M NaCl, 0.05% Tween-20, 0.5% BSA, 0.1 mM benzethonium, and 1% protease inhibitor
cocktail (Boston Bioproducts, Ashland, MA, USA). The homogenates were centrifuged at
10,000g for 30 min at 0°C. The supernatant was used for quantification of cytokines, i.e.
interleukin 1β (IL-1β), interleukin 6 (IL-6) and tumornecrosis factor-α (TNF-α) by ELISA kits
(R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Real-Time
qRT-PCR analysis was conducted as previously described[98]. The primer pairs were synthesized
by Integrated DNA Technologies, Inc. (Coralville, IA, USA) with the following primers: IL-1β F:
5′- ACCTGCTGGTGTGTGACGTT-3′, R: 5′-TCGTTGCTTGGTTCTCCTTG-3′; IL-6 F: 5′GAGGATACCACTCCCAACAGACC-3′, R: 5′- AAGTGCATCATCGTTGTTCATACA-3′A;
TNF-α F: 5′- AGCACAGAAAGCATGATCCG-3′, R: 5′-CTGATGAGAGGGAGGCCATT-3′;
β-actin F: 5′-AAGAGAGGCATCCTCACCCT-3′, R: 5′-TACATGGCTGGGGTGTTGAA-3′ The
copy number of each transcript was calculated with respect to the β-actin copynumber, using the
2−ΔΔCt method.
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6.2.11 Immunoblotting

Cells will be seeded in 150 mm culture dishes. After 24 h of incubation for cell
attachment, cells were treated with NBT (40 μM), M1 (40 μM), M2 (40 μM) or M3 (20 μM).
After another 24 or 48 h of incubation, cells were washed with ice-cold PBS, and collected with
cell scrapers. Whole cell lysates were prepared and then subjected to Western blotting analysis as
we previously reported[93]. Antibodies for p21Cip1/Waf1, cyclin D1, cleaved caspase-3, cleaved
caspase-9, and cleaved poly ADPribose polymerase (PARP) were purchased from Cell Signaling
Technology (Beverly, MA, USA). Anti-β-actin antibody was from Sigma-Aldrich (St. Louis,
MO, USA).
Whole cell lysate will be prepared as previously described[97]. RAW 264.7 cells were seeded in
10 mm culture dishes. After 24 h of incubation, cells were treated with 1 μg/mL LPS alone or
with serial concentrations of fecal extracts. After 24 h of incubation, the cells were harvested and
extracted with RIPA lysis buffer ((Tris-HCl pH 7.2, 25 mM; SDS 1000ppm; Triton X-100 1%;
sodium deoxycholate 1%; NaCl 0.15 M; EDTA 1 mM) (Boston Bioproducts, Ashland, MA,
USA) containing 1% protease inhibitor cocktail. The nuclear and cytosolic fractions were
prepared using NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher Scientific,
Rockford, IL, USA). Protein concentrations were determined using the BCA method (Pierce,
Rockford, IL, USA). The cell lysates were further subjected to Western blotting analysis as we
previously described[97]. Antibodies for iNOS, COX-2, p-IκBα, IκBα, PI3K, p-Akt, Akt, p-JNK,
JNK, HO-1 and PARP were obtained from Cell Signaling Technology (Beverly, MA, USA). NFκB p50, p65, c-Fos, c-Jun, p-PI3K, NQO1 and Nrf2 were obtained from Santa Cruz (Santa Cruz,
CA, USA). Anti β-actin antibody was from Sigma-Aldrich.
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6.3 Results and Discussion

6.3.1 Fecal levels of nobiletin metabolites
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Figure 6.2 Levels of Nobiletin and its metabolites N1, N2 and N3 in feces of CD-1 mice after
oral administration of 1000ppm nobiletin enriched diet over 9 weeks.

CD-1 mice were maintained on 1000ppm nobiletin enriched diet and standard diet for 9
weeks. The concentration of nobiletin, N1, N2, N3 in the feces of each group were determined by
HPLC. As can be seen from figure 6.2, the levels nobiletin did not change much during the 9
weeks’ period. The concentrations of metabolites were increasing over 9 weeks. The relative
abundance of nobiletin, N1, N2, N3 can be seen from figure 6.3. N3 was dominant at the first two
weeks, from week 6, N2 was dominant in feces. Overall, the level of N3 decreased and N2
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increased from week 1 to week 6. The composition tended to be stable after week 6. The ratio of
the compounds in week 9 is NBT: N1: N2: N3= 1:1.6:20:7.4.

Figure 6.3 Relative abundance of nobiletin and its metabolites N1, N2 and N3 in feces of CD-1
mice after oral administration of 1000ppm nobiletin enriched diet over 9 weeks.

The contrast that nobiletin level stayed unchanged while the concentrations of
metabolites growing over the period of administration could be attributed to the incomplete
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profile of the concentrations of metabolites. As can be seen from figure, there are some unknown
metabolites exist in the feces. In the current study, only N1, N2 and N3 were determined. It is
highly possible that other metabolites are highly concentrated in the first few weeks. In the last
few weeks, more nobiletin tend to be biotransformed into N2. The production of the metabolites
is the consequence of joint biotransformation of phase I and phase II metabolism as well as
microbial incubation of gut microbiome. Future studies are needed to elucidate the detailed
mechanism of the generation of the metabolites and the difference of composition in feces over
the administration period.

Figure 6.4 Chromatographs of metabolites extracts from feces of CD-1 mice after oral
administration of NBT group (1000ppm nobiletin enriched diet) and control group (base diet)
over 9 weeks.
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Figure 6.5 Levels of nobiletin, N1 N2 and N3 in A) Feces of CD-1 mice maintained on 1000ppm
NBT enriched diet for 9 weeks. B) Colonic mucosa of CD-1 mice maintained on 1000ppm NBT
enriched diet for 9 weeks.
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Feces is the rich source of metabolites localized in colon lumen. The colonic mucosa has direct
contact with these metabolites and are very likely to uptake them. The determination of levels of
NBT, N1, N2 and N3 in colonic mucosa and feces of CD-1 mice administrated with 1000ppm
NBT enriched diet are shown in figure 6.5. The relative abundance showed the same trend in the
colonic mucosa and feces, indicating the absorption of the metabolites into colonic enterocytes
mainly through passive diffusion. In order to acquire the metabolites to investigate their
biological activities, it is reasonable to extract the metabolites from mice feces.

6.3.2 Colonic metabolites of nobiletin showed growth inhibitory effects on human colon
cancer cells

First, we investigated the growth inhibitory effects of nobiletin colonic metabolites on
human colon cancer cells. HCT-116 and HT-29 were subjected to the treatments of metabolites
extract for 72h. In HCT-116, cells were treated with the fecal extract from the nobiletin group at
the concentration of 0.66 to 110 µg/L. The concentration of the feces extracts from the control
group was 8.3 to 83 µg/L. In HT-29, cells were treated with the feces extracts from the nobiletin
and control group at 8.3 to 83 µg/L. We found that NBT fecal extract exhibited stronger growth
inhibition on both cell lines in dose-dependent manner in comparison with the extract from the
feces of the control group.
Based on the results, the NBT fecal extract, which contains the colonic metabolites of
nobiletin showed much stronger anticancer activities on human colon cancer cell lines. The
inhibition effects are much higher than the effect of nobiletin of the fecal level (data not shown).
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Figure 6.6 The growth inhibitory effects of fecal extract from feces of mice maintained on
1000ppm NBT enriched diet (NBT fecal extract) and base diet (Ctrl fecal extract) on human
colon cancer cell lines A) HCT-116, B) HT-29. Cells were treated with serial concentrations for
72 hr. NBT fecal extract showed superior growth inhibitory effects in comparison to Ctrl fecal
extract.
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6.3.3 Colonic metabolites of nobiletin induced G2/M cell cycle arrest on human colon cancer
cells

Figure 6.7 Effects of fecal extract from feces of mice maintained on 1000ppm NBT enriched diet
(NBT fecal extract) and base diet (Ctrl fecal extract) on cell cycle progression of human colon
cancer cell line HCT-116. Cells were seeded in 6-well plates for 24h, and then treated with Ctrl
fecal extract and NBT fecal extract at the concentration of 40µg/L. After another 24h, cells were
collected and subjected to cell cycle analyses as described in methods section. All data represent
mean ± SD, and the asterisk in the bar charts indicated statistical significance of NBT fecal
extract-treated groups in comparison with the control and Ctrl fecal extract-treated groups based
on ANOVA followed by Tukey's HSD post-hoc test (p < 0.01, n =3).

103

To elucidate the mechanism of NBT fecal extract in inhibiting colon cancer cell
proliferation, cell cycle analysis was conducted on the colon cancer cell line HCT-116. As shown
in figure, the nobiletin fecal extract at the concentration of 40μg/L increased the percentage of
G2/M cell population compared to the control cells while the Ctrl fecal extract did not cause
significance change.

6.3.4 Colonic metabolites of nobiletin induced apoptosis in human colorectal cancer

Next, we examined the extent to which cell death pathways such as apoptosis contributed
to the inhibitory effect of NBT fecal extract and compared with those produced by Ctrl fecal
extract.
After 48 hrs of treatments with NBT fecal extract and Ctrl fecal extract concentrations,
early and late apoptotic cells were quantified by flow cytometry method with Annexin
V/Propidium Iodine (PI) double staining assay.
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Figure 6.8 Effects of fecal extract from feces of mice maintained on 1000ppm NBT enriched diet
(NBT fecal extract) and base diet (Ctrl fecal extract) on apoptosis of human colon cancer cells.
Cells were seeded in 6-well plates for 24 hr, and then treated with Ctrl fecal extract and NBT
fecal extract at 41.6µg/L for (A) HCT-116, and 15µg/L (B) HT-29. After another 48h, cells were
collected and subjected to apoptosis analyses described in methods section. All data represent
mean ± SD, and the asterisk in the bar charts indicated statistical significance of NBT fecal
extract group in comparison with the control and Ctrl fecal extract group at all concentration
based on ANOVA followed by Tukey's HSD post-hoc test (p < 0.01, n =3).

As shown in figure 6.8 A), for HCT-116 cells, treatment of NBT fecal extract at 41.6µg/L
significantly increased both the early apoptotic and late apoptotic population compared to control.
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In the contrast, the Ctrl fecal extract group did not change much in the apoptotic cell population
in comparison with control. In addition, after the treatment of NBT fecal extract to HT-29 cells at
the concentration of 15µg/L, early apoptotic population was increased compared to the control
group. When the cell was treated with Ctrl fecal extracts at the same concentration, no significant
increase of apoptotic cell population was observed. Our result indicates the NBT fecal extract can
efficiently induce the apoptosis in human colon cancer cells. HT-29 is more sensitive than HCT116 to the treatment of NBT fecal extract.

6.3.5 Colonic metabolites of nobiletin modulated key proteins related to cell proliferation
and apoptosis

In order to further elucidate the molecular mechanisms underlying the inhibitory effects
of colonic metabolites of nobiletin on human colon cancer cells, we determined the expression of
key protein markers related to cell proliferation and apoptosis. Immunoblotting analysis
demonstrated that NBT extracts caused extensive changes in the signaling proteins (figure 6.9).
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Figure 6.9 Effects of NBT metabolites extract on cell cycle and apoptosis related key proteins in
human colon cancer cells. HCT-116 (A) and HT-29 (B) cells were seed into 15 cm culture dishes
for 24h, and then cells were treated with NBT metabolites extract. After another 24h or 48h of
incubation, cells were collected for western blotting as described in methods section. The
numbers underneath of the blots represent band intensity (normalized to β-actin, means of three
independent experiments) measured by Image J software.

In HCT-116 and HT-29 cells, NBT fecal extract was treated at the concentration of
41.6µg/L and 15µg/L respectively. In HCT-116 cells, NBT fecal extract significantly increased
expression levels of cleaved caspase-3, p21Cip1/Waf1 and cleaved PARP and reduced the
expression of Cyclin E and p-Rb. Similarly, in HT-29, NBT fecal extract stimulated the increase
of the expression of cleaved PARP, and reduced the expression of Cyclin E and Bax.
Cell cycle and apoptosis are the hallmarks of carcinogenesis. Cancer is developed due to
the uncontrolled cell proliferation, which is associated with deregulation of cell cycle progression
and programmed cell death. Therefore, inducing cell cycle arrest and apoptosis in cancer cells is
potentially effective strategies for cancer prevention and treatment[99].
Cyclins are associated with the regulation of cell cycle progression by promoting the cell
cycle progression[100, 101]. However, the cyclins associated with the G2/M phase cell cycle
arrest (CDKs) did not show significant change in the NBT metabolites extract group compared to
the control. p53 and p21Cip1/Waf1 play key roles in carcinogenesis that are associated with both
apoptosis and cell cycle progression [102-105]. The increased expression of p21Cip1/Waf1
induced by NBT fecal metabolites indicated the effect of cell cycle regulation by colonic
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metabolites of nobiletin. Increased expression of cleaved caspase-3 and cleaved PARP are
associated with the promotion of apoptosis. The pathway initiated by cleaved caspase-3 can result
in the fragmentation of DNA and degradation of cytoskeletal and nuclear proteins[106]. The
increased expression of cleaved caspase-3 in HCT-116 by NBT fecal metabolites suggested the
caspase-dependent apoptosis was induced by colonic metabolites of nobiletin. The increased
expression of cleaved-PARP is associated with promotion of apoptosis[107]. As shown in the
result, NBT fecal extract can stimulate the expression of cleaved-PARP on HT-29 cells,
indicating the apoptosis was mediated by poly(adp-ribose).
The difference of the apoptosis and cell cycle arrest as well as the related protein
expression between suggests that the effects of NBT colonic metabolites may be cancer-type
and/or cell-type specific.

6.4 Conclusion

The results suggested that colonic metabolites of nobiletin was able to inhibit cancer cell
growth by impede cell cycle progression and increase programmed cell death. The biological
activities of nobiletin on colon after oral administration are the overall effects of the mixture of
nobiletin and its metabolites in the tissues. On assessing the biological activities of nobiletin, not
only should we take account nobiletin parent compound, but also its metabolites in the ratio of the
tissue level to reveal the real effects.
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CHAPTER 7
16.CONCLUDING REMARKS

Understanding the tissue distribution and biotransformation of dietary bioactive
components is the key to the elucidation of the mechanism of their biological activities. Oral
administration is the only route for the uptake of health beneficial agents from foodstuffs. It is
inevitable that the bioactive compounds are subjected to extensive first-pass effects and
subsequent biotransformation by intestinal enzymes and gut microbiome. The biological activities
of resultant compounds (metabolites) in most of the case are different from the parent compound.
It is essential to investigate the biological activities of those metabolites and determine the
quantity localized in the target tissues in order to make a conclusion to the overall effect of the
agent after oral administration.
Polymethoxyflavones (PMFs) are unique flavonoids almost exclusively found in
citrus plants (sweet oranges and mandarin oranges). Despite various biological activities of PMFs
such as anti-carcinogenesis, anti-inflammation, anti-angiogenesis, the biotransformation and
tissue distribution of PMFs after oral administration are still largely unknown. Since the in vivo
metabolites of PMFs possess potent biological activities according to many recent studies,
elucidating the tissue distribution of these metabolites are particular important for understanding
the mechanism of PMFs oral efficacy. Besides, the biotransformation of PMFs are also
interesting for its unique pattern of phase I and phase II metabolism, as well as the microbiome
interference. Basically PMFs undergo demethylation during the phase I metabolism and
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conjugation during the phase II metabolism. Microbiome involved in the demethylation of the
conjugated metabolites and further decomposition into small molecules.
This dissertation is focused on nobiletin (NBT) only. Another PMF that I studied during
my PhD using the same methodology is 5-demethylatednobiletin (5-DN). The former is the most
abundant PMF in citrus peels and the latter is the hydrolysis product of nobiletin in aged orange
peels. The metabolites of both NBT and 5-DN possess potent chemopreventive activities. The
dissertation only includes NBT part.
In order to acquire a thorough understanding of PMFs tissue distribution profile after
long time oral administration, we applied oral administration to three types of rodents, i.e. A-J
female mice, CD-1 male mice and male F344 male rats at three different doses (250ppm, 500ppm
and 1000ppm). PMFs were administrated repeatedly by mixing with standard diet over a few
weeks to mimic the long-term dietary consumption of PMFs from food or dietary supplements.
Despite the minor difference between different rodent types, PMFs are extensively
biotransformed into metabolites in gastrointestinal tract (GIT), including the ones that have been
proved to exhibit stronger biological activities than their parent compounds. It is interesting to
observe that the extremely low levels of parent compound found in excretion path (feces, urine
and bile juice). Instead, the metabolite 4’-demethylnobiletin (N2) is the major metabolite for all
rodent types, followed by 3’4’-didemethylnobiletin (N3). 3’-demethylnobiletin (N1) is the least
abundant metabolites for all rodents, yet the most potent one according to previous cell culture
studies (on lung cancer, colon inflammation and cancer). Opposed to GIT, it is also interesting to
see a larger portion of parent compound accumulated in peripheral tissues as well as serums. NBT
brain level was the higher than its metabolites, which may suggest that it can pass the blood-brain
barrier (BBB) due to its hydrophobic structure.
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In spite of the fact that the metabolites in most of the tissues including small intestine (SI)
are in conjugated form, one interesting observation is that almost all metabolites found in cecum
and colon tissues as well as digesta (food under digestion in intestinal lumen) are in free form. To
further elucidate the deconjugation mechanism of those metabolites in cecum and colon, and to
investigate in the biotransformation of PMFs to a deeper extent, we segmented the intestine into
multiple parts and determined the metabolites in the mucosa as well as digesta in each segments.
Our result showed the extensive phase I and phase II metabolism (demethylation and
conjugation) in liver, proved by the high level of conjugated metabolites found in liver and
gallbladder, as well as the demethylation and conjugation metabolites produced by liver S-9
fraction.
Moreover, the increased levels of metabolites from the front to the distal part of the small
intestine proved the biotransformation ability of small intestine mucosa. Furthermore, by
incubating the small intestine digesta with cecum microbiome isolates, we proved the
deconjugation of some conjugated metabolites can be attributed to the microbiome.
Since the free form metabolites of PMFs possess stronger biological activities than their
parent compounds while conjugated metabolites barely possess any biological activities, the
microbiome contributed to the activation of PMFs biological activities in colonic tissues.
Therefore, we further determined the anti-cancer and anti-inflammation properties of PMFs
colonic metabolites. The extractions of colonic digesta are a group of NBT metabolites include
the previous identified N1, N2, N3 as well as a great portion of unknown metabolites. Together,
these metabolites showed stronger anti-cancer and anti-inflammation properties than the same
concentration of nobiletin. This is a great explanation why we should not just focus on the parent
compound when studying the biological activities.
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As a summary, these studies provided a thorough information of PMFs in vivo
biotransformation, the tissue distribution of biological activity related metabolites as well as the
implication of the metabolism on colorectal cancer and inflammation.
The future work can be carried out to further identify new metabolites of PMFs. In
addition, the role of gut microbiome can be further investigated in the aspect of biotransformation
and its implication on the biological activities of PMFs. Moreover, further investigation can be
focused on the unique characteristic of PMFs that the metabolites possessing higher biological
activities than the parent compounds. There is potentially structure-activity relationship that can
be applied to many other compounds once discovered. Since food matrix is a complicated system
containing multiple biological active agents. Synergy of the bioactive agents from food should
also be considered in the future investigation of potential biological effects.
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17.APPENDICES
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APPENDIX

THE TABLES

Table 1. The tissue distribution of NBT and its 3 metabolites N1, N2 and N3 in A/J mice after 14 weeks of oral administration with 250ppm NBT
enriched diet
N2(free
NBT

N1(free form)

N1 (Conjugated)

N3 (Free
N2 (Conjugated)

form)

N3 (Conjugated)
form)

Stomac
11.2±0.80

0.11±0.02

0.05±0.02

2.01±0.79

1.01±0.79

0.72±0.31

0.10±0.03

SI

0.13±0.02

0.04±0.01

0.20±0.10

11.8±2.70

6.91±3.08

0.33±0.05

0.45±0.13

Cecum

0.08±0.04

0.33±0.05

-

9.07±1.27

1.05±0.42

5.74±0.92

0.56±0.17

Colon

1.13±0.09

3.64±0.49

2.27±0.49

4.11±1.11

0.54±0.11

0.41±0.11

0.23±0.11

h
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Liver

1.21±0.20

0.24±0.05

0.19±0.05

9.73±1.33

1.08±0.73

0.49±0.11

0.42±0.11

Spleen

3.91±0.07

0.30±0.07

0.13±0.07

0.09±0.02

-

0.01±0.00

-

Brain

1.98±0.40

0.40±0.08

0.14±0.08

0.36±0.11

0.22±0.06

0.03±0.01

-

Serum

-

0.03±0.00

0.02±0.01

0.34±0.05

3.32±0.47

-

-
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Table 2: Tissue distribution of NBT in female A/J mice, male CD-1 mice and male F344
rates after oral administration of 500ppm NBT enriched diet

for 14 weeks
Tissue

Rodent type
A/J

CD-1

Rat

Stomach

25.31±1.82

69.95±20.70

35.76±38.06

SI

2.37±0.60

2.03±1.17

12.61±12.12

Cecum

0.86±0.25

6.66±3.78

11.01±1.79

Colon

0.86±0.34

2.40±1.29

1.39±0.26

331.61±4.06

667.00±93.91

197.43±75.46

SI digesta

8.81±2.29

26.47±12.33

87.80±28.11

Cecum digesta

6.40±2.83

18.98±9.79

39.38±18.01

Feces

3.03±0.93

160.63±74.83

200.44±-

Liver

1.41±0.18

5.34±1.36

0.95±0.61

Spleen

31.88±4.98

15.21±10.58

5.76±6.13

Stomach digesta
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Serum

7.90±2.32

3.90±2.32

-

Brain

5.01±0.35

3.34±0.95

6.88±2.83

“-” indicate not detectable
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Table 3: Tissue distribution of N1 in female A/J mice, male CD-1 mice and male F344 rates after oral administration of 500ppm nobiletin
enriched diet for 14 weeks
Rodent type

Rodent type

Tissue

Tissue
A/J

CD-1

Rat

A/J

CD-1

Rat

0.076±0.0070

-

0.0086±0.018

0.046±0.022

0.26±0.19

0.19±0.078

SI

1.14±0.66

0.020±0.037

0.43±1.60

SI

0.20±0.23

7.35±2.30

20.94±2.27

Cecum

0.67±0.15

6.26±0.82

7.03±4.39

Cecum

0.094±0.17

-

13.24±8.43

Colon

1.26±0.16

1.98±0.60

1.47±0.33

Colon

0.23±0.20

-

0.62±0.14

0.044±0.0070

4.15±1.60

-

0.067±0.0045

-

0.98±0.030

SI digesta

0.12±0.025

0.36±0.22

9.60±2.71

SI digesta

3.04±0.23

6.74±4.72

67.93±6.92

Cecum digesta

0.43±0.095

28.12±2.88

37.43±8.46

Cecum digesta

0.019±0.063

-

-

Feces

1.67±0.56

54.75±12.11

39.68±5.63

Feces

-

-

-

Liver

0.12±0.028

2.00±0.022

0.22±0.29

Liver

0.13±0.045

0.19±0.088

1.88±0.97

Stomach

Stomach digesta

Stomach

Stomach digesta
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Spleen

6.35±3.62

0.33±0.20

0.016±0.022

Spleen

11.52±3.04

0.33±0.083

0.36±0.097

Serum

0.55±0.22

0.21±0.067

-

Serum

0.17±0.15

0.61±0.24

-

Brain

0.47±0.095

0.046±0.020

0.047±0.042

Brain

2.00±0.027

0.15±0.074

0.098±0.0064

“-” indicate not detectable
Table 4: Tissue distribution of N2 in female A/J mice, male CD-1 mice and male F344 rates after oral administration of 500ppm nobiletin
enriched diet for 14 weeks
Rodent type

Rodent type

Tissue

Tissue
A/J

Stomach
SI
Cecum

CD-1

Rat

A/J

CD-1

Rat

1.55±0.15

12.99±6.42

0.02±0.13

Stomach

1.77±0.47

8.04±7.47

0.94±0.57

5.7±1.04

14.99±6.51

31.18±22.59

SI

18.5±7.9

40.24±11.14

19.46±3.44

12.76±1.66

171.68±23.62

22.64±20.9

Cecum

0.84±2.13

-

2.3±3.84
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Colon
Stomach
digesta

6.07±2.14

21.08±3.67

31.45±4.04

1.09±0.05

44.64±14.54

3.49±2.11

-

9.01±6.35

151.29±54.34

42.43±5.54

264±43.57

164.43±52.04

SI digesta
Cecum
digesta
Feces

Colon
Stomach
digesta
SI digesta
Cecum

-

-

1.18±0.10

4.92±4.54

2.52±2.36

62.07±10.7

12.16±15.06 98.69±17.79

4.54±1.97

-

-

Feces

92.9±38.44

-

-

digesta

135.6±13.7 1018.63±153.04 2217.37±625.32

1.82±3.15

Liver

9.63±2.46

14.84±4.56

5.30±1.69

Liver

4.27±0.12

3.21±3.07

9.35±3.61

Spleen

0.24±0.03

7.89±5.88

0.13±0.18

Spleen

0.44±0.02

3.63±1.57

0.72±0.12

Serum

0.53±0.06

0.38±0.18

-

Serum

4.75±0.67

5.63±4.64

-

Brain

1.65±0.10

0.090±0.030

0.12±0.04

Brain

0.46±0.07

1.36±0.72

0.18±0.06

“-” indicate not detectable

122

Table 5: Tissue distribution of N3 in female A/J mice, male CD-1 mice and male F344 rates after oral administration of 500ppm nobiletin
enriched diet for 14 weeks
Rodent type

Rodent type

Tissue

Tissue
A/J

CD-1

Rat

Stomach

0.94±0.27

12.15±4.57

0.05±0.39

SI

0.37±0.090

1.67±0.66

6.87±1.53

Cecum

23.87±5.08

160.67±11.84

Colon

14.02±3.37

Stomach digesta

SI digesta

Cecum digesta

Feces

A/J

CD-1

Rat

Stomach

1.21±0.63

-

0.36±0.20

SI

22.15±1.87

26.58±7.87

15.02±1.63

57.69±56.71

Cecum

0.99±6.70

-

50.20±14.52

2.59±0.83

10.36±1.02

Colon

3.86±3.37

-

0.04±0.03

0.77±0.090

51.19±24.94

0.09±3.46

0.40±0.09

-

15.65±14.31

0.11±0.18

1.08±1.57

34.78±3.28

16.37±4.50

21.86±12.09

73.08±8.31

61.05±16.27

638.25±285.57

31.36±11.65

25.04±8.21

-

-

606.77±176.10

1240.09±72.11

389.08±92.31

-

-

-

Stomach
digesta
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SI digesta
Cecum
digesta
Feces

Liver

3.37±0.92

0.48±0.10

7.54±1.42

Liver

3.07±0.92

1.93±0.59

0.29±0.17

Spleen

0.19±0.06

8.91±8.59

0.10±0.14

Spleen

0.12±0.06

0.97±0.44

0.91±0.22

Serum

1.08±0.16

-

-

Serum

1.07±0.16

2.54±0.91

-

Brain

1.09±0.04

-

0.07±0.08

Brain

1.02±0.04

0.07±0.04

0.11±0.04

“-” indicate not detectable
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